Director greeting
Our role as pharmacists is to provide patients with correct and safe medicines. In addition to explaining the preparation of medicines and topical medicines as well as their actions and side effects, we also discuss problems with patients about medicines, such as what precautions should be taken when taking medicines and whether the effects of medicines are properly manifested. I would like to have a firm grasp of each patient's daily life and be involved in all aspects of medicine that are closely related to the daily lives of each patient. In addition, we will deepen cooperation with insurance pharmacies so that patients can continue to take medicines with peace of mind even after they are discharged from the hospital. I will continue.
Keeping in mind that “Where there is medicine, there is a pharmacist,” all pharmacy department members will work together to ensure that patients are satisfied with their peace of mind. If you have any questions or concerns about your medicine, please feel free to ask your pharmacist.
Pharmacy staff
| Pharmacy Department Director | Nobuyuki Muroi |
|---|---|
| Deputy Director of Pharmacy Department | Hiroaki Ikesue |
| Deputy Director of Pharmacy Department | Masaki Hirabatake |
| Deputy Director of Pharmacy Department | Manabu Kume |
| Chief of Pharmacy Department | Toshihiko Oda |
| Assistant to Hospitl Director and Counsilor | Toru Hashida |
In addition, 13 Chief Examiners and 2 Chiefs
63 full-time pharmacists, 9 resident pharmacists
| Pharmacy Department Director | 1 person |
|---|---|
| deputy Director | 3 people |
| Chief | 1 person |
| Assistant to Hospitl Director and Counsilor | 1 person |
| chief inspector | 13 people |
| Chief | 2 people |
| pharmacist | 63 (full-time), 4 (part-time) |
| Pharmacist Resident | 9 people |
| Clerk / pharmacy assistant | 10 people |
| total | 86 (76 pharmacists) |
Guidance, specialty, certified pharmacist
| Japan Pharmaceutical Society | Instruction pharmacist | 4 people |
|---|---|---|
| Pharmacist specializing in medical pharmacy | 9 people | |
| Cancer guidance pharmacist | 2 people | |
| Oncology pharmacist | Five people | |
| Drug therapy specialist pharmacist | 1 person | |
| Japan Hospital Pharmacists Association | Cancer drug therapy certified pharmacist | 2 people |
| HIV infection certified pharmacist | 1 person | |
| Infection Control Certified Pharmacist | 2 people | |
| Certified pharmacist of Nichiyaku Hospital | 24 people | |
| Lifelong Training Certified Pharmacist | 13 people | |
| Japanese Society of Clinical Oncology | Outpatient cancer treatment certified pharmacist | 3 people |
| Diabetes Educator Certification Organization | diabetes educator | Five people |
| Japanese Society of Medicine and Diabetes | Diabetes drug therapy certified pharmacist | 2 people |
| Japan Society of Medical Informatics | medical information technician | 1 person |
| Japanese Society of Palliative Medicine | Palliative pharmacotherapy certified pharmacist | 3 people |
| Temporary Guidance Pharmacist for Palliative Medicine | 2 people | |
| Narcotics education certified pharmacist | 1 person | |
| Japanese Society for Clinical Nutrition and Metabolism | NST Professional Therapist | 4 people |
| Perioperative/Emergency Intensive Care Therapist | 1 person | |
| Japanese Society For Emergency Medicine | Emergency certified pharmacist | 1 person |
| Japan Gerontological Society | Geriatric Pharmacy Licensed Pharmacist | 1 person |
| Japanese Society for Clinical Toxicology | Certified Clinical Toxicologist | 1 person |
| Japanese Society of Clinical Pharmacology | Certified CRC | 2 people |
| Japanese Society of Chemotherapy | Antibacterial chemotherapy certified pharmacist | 2 people |
| The Japanese Circulation Society | heart failure educator | 3 people |
| Japan Kidney Association | renal failure educator | 1 person |
| Japan Pharmacist Training Center | Training certified pharmacist | 6 people |
| Certified Practical Training Guidance Pharmacist | 10 people | |
| Pediatric drug therapy certified pharmacist | 2 people | |
| Chinese herbal medicine and herbal medicine certified pharmacist | 1 person | |
| Japan Anti-Doping Agency | sports pharmacist | 1 person |
| Certified by the Japan Clinical Nutrition Association | NR/Supplement Advisor | 1 person |
| Disease Control Division, Health Bureau, Health and Welfare Department Hyogo Prefecture | hepatitis medical coordinator | 2 people |
| Hyogo Prefecture Federation of Diabetes Educators | Diabetes Educator Hyogo | 2 people |
| Japanese Society for Clinical Trials | Certified GCP Passport | 1 person |
About the duties of the pharmacy department
The Department of Pharmacy plays a role in improving the quality and safety of medical care through proper use and proper management of pharmaceuticals, and participates in team medical care as a drug expert. By stationing pharmacists in all wards, pre-hospital preparation centers, and Regional Medical Cooperation Center, we have established a system to ensure the continued safety of pharmacotherapy from inpatients to outpatients and at home.
prescription dispensing
By operating a dispensing system (dispensing audit system, automatic medicine bag creation, automatic tablet packaging, prescription audit system) linked to the electronic medical record system for both inpatients and outpatients, we are working to ensure accurate dispensing and efficiency in dispensing. . In addition, the introduction of a prescription drug delivery system has made it possible to deliver drugs quickly and accurately. In 2021, we will introduce a robot dispensing room (automatic drug picking device, powdered drug dispensing robot, picking support system) to digitize dispensing.
injection drug dispensing
We check and dispense injection medicines for each patient and every day in all wards except the intensive care unit. Using an automatic injection drug dispensing device linked to the injection drug ordering system, the drug is put into a tray and dispensed for each patient and application. We strive to provide safe injection drugs by checking the patient's condition, dosage, administration method, formulation changes and side effects.
Chemotherapy room duties
For all outpatient and inpatient cancer chemotherapy, we carry out sterile preparation in a safety cabinet after checking the prescription contents. In 2017, we introduced an anticancer drug preparation robot to further improve efficiency.
Formulation, injectable aseptic preparation
In-hospital formulations are prepared when over-the-counter drugs cannot meet the diverse needs of patients according to their condition. In-hospital special preparations are preparations that are doctor and not available on the market, even if they are essential for the treatment of specific patients. In addition, high-calorie infusions that must be mixed aseptically are prepared in a clean bench.
Drug management guidance work, ward pharmacy work
All wards, including the critical care center and intensive care units, are staffed by pharmacists. In addition to providing medication guidance at the patient's bedside, we strive to provide safe and effective drug treatment, such as improving patient adherence, supporting self-management, and proposing prescriptions to avoid side effects. Furthermore, we are actively participating in regional medical care through diabetes classes, heart disease classes, kidney disease classes, digestive disease classes, and respiratory classes that outpatients can also participate in.
Admission and discharge support work
At the pre-hospital preparation center, we check the use of regular medicines, health foods, and supplements before hospitalization, and grasp the medicines to be discontinued before surgery to facilitate post-hospital treatment. We also review medications prescribed by other medical institutions to check for overlaps and interactions. Furthermore, in 2021, we will set up a perioperative support team to provide support for early recovery and social reintegration of patients undergoing surgery, with pharmacists participating.
As for discharge support, it is safe and effective for patients even after discharge through the creation of an inter-facility drug information provision form for the medical institution to which the patient is transferred and cooperation with medical institutions and insurance dispensing pharmacies by pharmacists assigned to the Regional Medical Cooperation Center. We are working hard to ensure that you receive the best possible medication.
Drug concentration monitoring (TDM)
Analysis is based on blood concentration measurement results of antibacterial agents, mainly vancomycin and teicoplanin, which are anti-MRSA agents, antifungal agents, and immunosuppressants. Setting the optimal dosage for each patient contributes to ensuring efficacy and preventing side effects.
Medicine management
We use an inventory management system to efficiently manage the purchase, storage, and supply of pharmaceuticals to each department. Pharmacists regularly check wards and outpatient drugs, and manage drugs such as appropriate quantities and deadlines.
drug control
Medicinal narcotics are drugs that have excellent analgesic effects but require strict control. Since drug abuse is a major social problem, its handling and storage methods are strictly regulated, and we promote the management and proper use of medical drugs within hospitals based on the law.
Pharmaceutical information management
Obtain drug information necessary for the proper and safe use of drugs from the Ministry of Health, Labor and ministry of Health, Labor and Welfare notation, the Pharmaceuticals and Medical Devices Agency (PMDA), drug manufacturers, literature, etc. First, we provide information in cooperation with pharmacists in each department.
Urgent and important information, such as emergency safety information and safety bulletins, should be sent to prescribing doctor and other hospital staff through e-mail, direct contact, electronic medical record postings, etc. We provide information to our staff as soon as possible.
In addition, support for pharmacists in each department, response to questions and consultations from doctor, nurses, and hospital staff, pharmaceutical affairs committee secretariat operations (management of the pharmaceutical affairs committee, response to voluntary recalls, shortages, etc., generic drug We also provide proposals for the introduction of drugs, etc.) and support reporting of side effects.
In addition, support for pharmacists in each department, response to questions and consultations from doctor, nurses, and hospital staff, pharmaceutical affairs committee secretariat operations (management of the pharmaceutical affairs committee, response to voluntary recalls, shortages, etc., generic drug We also provide proposals for the introduction of drugs, etc.) and support reporting of side effects.
Clinical trial/clinical research support
The Clinical Research and Innovation the development of new treatment methods, drugs and medical devices, and the optimization of existing medical technology. As the core of the administration and support department, pharmacists provide support services for the safe and smooth conduct of ethical and scientifically high-quality clinical trials and clinical research. In addition to proper management of investigational drugs, we also collect and manage safety-related information and other information.
Pharmacist outpatient
We are working to improve services for outpatients, such as providing detailed explanations of medicines to outpatients, checking for side effects, and understanding the medications that are regularly used by patients scheduled to be hospitalized.
Oral medicine confirmation outpatient
At the specialized booth and the pre-hospitalization preparation center, we will check the patient's usual medications before hospitalization, check whether they are adopted by our hospital, introduce alternative drugs, and check the status of discontinuation of drugs that have been discontinued before surgery.
Oral anticancer drugs Pharmacist outpatient
Before seeing a doctor, we check the patient's medication status and side effects (pre-examination), describe the patient's condition in the medical record, and, if necessary, propose a prescription to the doctor.
Interstitial pneumonia pharmacist outpatient
We check the medication status and side effects of interstitial pneumonia treatment drugs before the doctor 's examination, record the patient's condition in the medical chart, and propose a prescription to the doctor if necessary.
Hepatitis C drug pharmacist outpatient
In order to maximize the effects of direct-acting antiviral drugs, which are therapeutic drugs for hepatitis C virus, interactions with regular drugs should be minimized, necessary medication instructions should be given, and medication status should be checked. In addition, it is explained that the risk of cirrhosis and liver cancer remains even after recovery, and the necessity of continued examination and examination is also explained.
Thalidomide/Lenalidomide/Pomalidomide Outpatient pharmacist
For patients who have been prescribed thalidomide, lenalidomide, or pomalidomide, we provide guidance on proper use and management methods, confirmation of drug management status, and a deeper understanding of the importance of taking medication when administering medication after a doctor 's examination. I'm here.
HIV pharmacist outpatient
We will conduct interviews as needed to check for side effects of HIV treatment drugs and concerns about illness, and support so that treatment can be carried out smoothly. When prescribing for the first time, we have an interview with the doctor before the examination and propose the appropriate drug.
Participation in team medical care
I am active in various situations as a member of the medical team.
Outpatient chemotherapy team
As a member of team medical care, we contribute to the implementation of safe and secure cancer chemotherapy by checking prescriptions of anticancer drugs, managing regimens, preparing aseptic mixtures, and explaining side effects to patients. In addition, we cooperate with insurance pharmacies to support the safe continuation of outpatient anticancer drug treatment.
HIV/AIDS support team
Mental anxieties and physical disabilities caused by having to take medicines that require careful administration, medicines with unique side effects, and medicines that are difficult to take for a long period of time over a lifetime. We work together to provide a variety of support.
palliative care team
In the palliative care outpatient clinic, I attend medical examinations by doctor and nurses, propose medications for alleviating symptoms, and provide medication guidance to patients. In addition, for inpatients who have been consulted by the palliative care team, we work with team members to understand daily changes in symptoms and intervene from a pharmacological point of view to address various clinical problems.
Nutrition Management Team (NST)
We work together with other professions to ensure that all patients receive proper nutritional management, which is the basis of treatment. At core team conferences and satellite NSTs in hospital wards, we make proposals from a pharmaceutical perspective on parenteral nutrition planning, electrolyte management, complications, etc., and also participate in educational activities.
Infection Control Team (ICT)
We strive to prevent nosocomial infections by utilizing the expertise of pharmacists, such as advice on the proper use of antibacterial drugs and disinfectants, usage statistics, and TDM.
Antimicrobial Stewardship Team (AST)
We help you get the best treatment for infectious diseases. We have appointed a pharmacist as a full-time employee and are working to promote the proper use of antibacterial drugs.
risk management
We also participate in the activities of the Risk Management with the aim of improving the quality and safety of medical care. As a member of the medical team, I contribute not only to the reporting of risk cases within the pharmacy department, but also to the consideration and planning of countermeasures for all risk cases related to drug treatment within the hospital.
Diabetes Therapy Guidance Team
As a diabetes educator, I support patients so that they can proactively engage in treatment and self-manage. By participating in conferences, exchanging information with other professions, and accompanying patients on rounds, we are working to fully understand the treatment policy and the patient's condition, and to provide support throughout the treatment process.
cardiac rehabilitation team
It explains in an easy-to-understand manner the purpose and precautions for use of cardiovascular drugs. We participate in conferences and strive to provide effective drug treatment while collaborating with other occupations.
heart failure team
For end-stage heart failure patients, we consider not only the patients themselves but also the surrounding environment such as their families, and we are examining treatment policies that look ahead to post-discharge with a multidisciplinary team. The pharmacist proposes the appropriate drug therapy for the patient and strives to ensure that the treatment can be continued safely.
interstitial pneumonia support team
We support the treatment of patients with interstitial pneumonia through multidisciplinary collaboration. Pharmacists explain to patients and their families who are starting outpatient drug therapy such as antifibrotic drugs about precautions to take, side effects and countermeasures, and support the continuation of treatment while monitoring side effects.
Psychiatry Liaison Team
For inpatients with delirium, peripheral symptoms of dementia, and mental symptoms such as depression, we provide multidisciplinary support so that treatment can be continued smoothly through drug treatment and psychoeducation, etc., with an eye toward discharge from the hospital.
Dementia care team
We provide multidisciplinary support for inpatients who have difficulty in caring for dementia. The pharmacist will suggest medications to help with care, such as polypharmacy, sleeping pills, and pain control.
Resident system
Overview 研修規程 研修プログラム 自己評価調査票 外部評価報告書For those who wish to become a resident or staff member
About the tour of the pharmacy department
The pharmacy department of our hospital holds tours for pharmacist residents and staff on the morning of the second Thursday of each month (online) and the morning of the third Thursday of each month (in-hospital format). We look forward to your participation.
Depending on the situation of the new coronavirus infection, we may not be able to meet your request for a visit-style tour. Please note.
Application method
Please be sure to fill in 1 to 5 below and apply by e-mail at least 14 days before the tour date.
- Name (furigana)
- sex
- University name, grade
- Desired schedule (please let us know up to your second choice)
- Preferred method of visit (visit or online)
Application destination
c_pharm-publicity@kcho.jp (The subject should be [Tour Application].)
If you have any other questions, please contact us at the number below.
Contact information
responsible person
Ryo Tamura, Public Relations and Visitors, Pharmacy Department
Tel. 078-302-4321 (representative)
For regional medical institutions
For insurance pharmacies
About inquiries about out-of-hospital prescriptions
For inquiries regarding out-of-hospital prescriptions,
- For details of prescription, contact the doctor through the pharmacy department
- For prescriptions such as insurance, please contact the accounting department (medical affairs section).
Please contact us. Since the prescribing doctor may be under examination, please contact us after summarizing your doubts.
About medication information sheet (tracing report)
At our hospital, we have prepared a medication information sheet (tracing report).
Information that is deemed desirable to be provided to the prescribing doctor, although the immediacy is low, is collected by the insurance pharmacy by fax (addressed to the pharmacy department), and information is transmitted to the doctor for information sharing. .
Please use the medication information provision form after confirming the operation of the attachment below.
Regarding outpatient cancer chemotherapy, please refer to the following "Drug Information Sheet for Outpatient Cancer Chemotherapy Please use from.
Fax address
(078) 302-5534 pharmacy department
About providing information to our hospital after changing to generic drugs
We will change the method of providing information from the conventional FAX to the following method.
- After changing to a generic drug, please give the patient an instruction manual or specify the details of the change in the medicine notebook.
- Please instruct the patient to show these to the doctor the next time he or she visits our hospital.
Newly Adopted and Deleted Drugs
List of adopted chemicals (as of April 2024)April 5, 2024: Alternative medicines for shipment adjustments, shortages, etc.
alternative medicine
- Amantadine hydrochloride tablets 50 mg "SAWAI" (alternative to Symmetrel tablets 50 mg)
April 2, 2020 Newly adopted drugs and changed/deleted drugs
Adopted chemicals
- Zocoba tablets 125mg
- Polyful fine grain 83.3%
- Poliflu tablets 500mg
- Isodine Gargle solution 7% 30mL
Introduction of generics
- Bepridil Hydrochloride Tablets 50mg "TE"
Remove chemicals
- Coronel fine grain 83.3%
- Coronel tablets 500mg
- Povidone-iodine Gargle 7% "Nichiiko" 30mL
- Excelase combination tablets
March 22, 2020 Alternative plans for shipping adjustments, out-of-stock items, etc.
alternative medicine
- Kracie Goreisan Extract Fine Granules 2.0g/package (substitute for Tsumura Goreisan Extract Granules (Medical Use) 2.5g/package)
March 6, 2020 Alternative medicines for shipping adjustments and out-of-stock items
alternative medicine
- Takecab tablets 10mg (alternative to Takecab OD tablets 10mg)
- Takecab tablets 20mg (alternative to Takecab OD tablets 20mg)
March 5, 2020 Newly adopted, changed and deleted drugs
Adopted chemicals
- Trimebutine maleate tablets 100mg "Towa"
- Sogruya subcutaneous injection 15mg (for out-of-hospital use only)
- Colletiment tablets 9mg (for out-of-hospital use only)
Remove chemicals
- Celequinone tablets 100mg
- Opium tincture (as needed)
- Inolet 30R Injection (out-of-hospital medicine, as needed)
February 2, 2020 Newly adopted drugs and changed/deleted drugs
Adopted chemicals
- Orkedia tablets 4mg
Remove chemicals
- Stockrin Tablets 600mg (drug for outside hospitals only)
Cancer chemotherapy regimen
Introduction
The regimens published here were reviewed and approved by the Cancer Chemotherapy Committee of Kobe City Medical Center General Hospital. This document is provided for the purpose of proper administration management of patients undergoing cancer treatment at our hospital, and is not intended to be used for any other purpose. Dosage, dosing schedule, and supportive care may vary depending on the patient's condition.
Cancer chemotherapy regimen
Cancer chemotherapy regimen Lung cancer
Update date and time: November 29, 2023
| P16-101 | (With radiotherapy) PTX Weekly | |
| P16-101 | (No cure) PTX Weekly | |
| P15-204 | Every 3 weeks S1/CDDP | |
| A15-202 | Abraxane (d1,8,15)/CBDCA triweekly | |
| A15-101 | Abraxane weekly | |
| P15-404 | ADOC | |
| B17-202 | Afatinib daily/Bev triweekly | |
| A21-101 | AMR (35) (d1-3) triweekly (NSCLC) | |
| A21-101 | AMR (40) (d1-3) triweekly (SCLC) | |
| A19-302 | Atezo/CBDCA(5)/ETP(100)(d1-3)q3w | |
| A19-302 | Atezo/CBDCA/nabPTX(d1,8,15) q3w | |
| A19-304 | Atezo/CDDP/PEM q3w | |
| A19-202 | Atezo/PEM q3w maintenance therapy | |
| A19-303 | Atezo/PEM/CBDCA q3w | |
| A18-102 | Atezolizumab triweekly (NSCLC) | |
| A18-202 | Atezolizumab/Bev q3w maintenance therapy | |
| A18-402 | Atezolizumab/Bev/CBDCA/PTX q3w | |
| B15-102 | Bev triweekly | |
| A15-303 | Bev/Abraxane (d1,8,15)/CBDCA triweekly | |
| D16-202 | Bev/DTX triweekly | |
| G15-202 | Bev/GEM(d1,8) triweekly | |
| P15-203 | Bev/PEM (500) triweekly | |
| P15-304 | Bev/PEM/CBDCA triweekly | |
| P15-306 | Bev/PEM/CDDP triweekly | |
| P16-202 | Bev/PTX (d1,8,15) monthly | |
| P16-303 | Bev/PTX(d1,8,15)/CBDCA monthly | |
| P16-303 | Bev/PTX/CBDCA triweekly | |
| C19-101 | CBDCA (30) daily + RT (NSCLC) | |
| C15-203 | CBDCA(5)/ETP(80) (d1-3) triweekly | |
| P15-101 | CDDP it | |
| P15-201 | CDDP it/ADM it | |
| P15-205 | CDDP(80)/ETP(100) (d1-3) triweekly | |
| P15-201 | CDDP (d1-3)/ETP (d1-3) triweekly | |
| V15-403 | CODE 1st week | |
| V15-202 | CODE 2nd, 4th, 6th, 8th week | |
| A15-303 | CODE 3rd, 5th, 7th, 9th week | |
| CPT16-101 | CPT-11 (100) weekly (lung cancer) | |
| CPT15-202 | CPT-11(d1,8,15)/CBDCA monthly | |
| CPT15-204 | CPT-11 (d1,8,15)/CDDP monthly (NSCLC) | |
| CPT15-204 | CPT-11 (d1,8,15)/CDDP monthly (SCLC) | |
| D16-101 | DTX (60) triweekly (lung cancer) | |
| D16-202 | DTX(d1,8)/CDDP(d1,8) monthly | |
| D16-202 | DTX/CBDCA triweekly (lung cancer) | |
| D16-203 | DTX/CDDP triweekly | |
| D20-302 | Durva(BW≦30)/CBDCA/ETP(d1-3)q3w | |
| D20-303 | Durva(BW≦30)/CDDP/ETP(d1-3)q3w | |
| D23-101 | Durva(Treme/Durva)q4w maintenance first time/third time~ | |
| D20-302 | Durva/CBDCA/ETP(d1-3)q3w | |
| D20-303 | Durva/CDDP/ETP(d1-3)q3w | |
| D23-201 | Durva/PEM(Treme/Durva)q4w maintenance first/third time~ | |
| D23-101 | Durvalumab after CRT q4w(BW>30kg)(NSCLC) | |
| D23-101 | Durvalumab after CRT q4w(BW≦30kg)(NSCLC) | |
| D20-101 | Durvalumab (BW ≤ 30) maintenance q4w (ES-SCLC) | |
| D20-101 | Durvalumab maintenance q4w (ES-SCLC) | |
| B15-202 | Erlotinib daily/Bev triweekly | |
| E15-102 | ETP (d1-3) triweekly | |
| B17-202 | Gefitinib daily/Bev triweekly | |
| G15-101 | GEM(d1,8) triweekly (lung cancer) | |
| G15-202 | GEM(d1,8)/CBDCA(AUC=4-6) triweekly | |
| G15-204 | GEM(d1,8)/CDDP triweekly | |
| G15-101 | GEM (d1,8,15) monthly (lung cancer) | |
| G19-304 | Neci(d1,8)/GEM(d1,8)/CDDP triweekly | |
| N19-101 | Necitumumab(d1,8) triweekly maintenance therapy | |
| N23-301 | Nivo/GEM(d1,8)/CDDP q3w (preoperatively) (squamous cell carcinoma) | |
| N20-203 | Nivo(d1,22)/Ipi(d1) q6w | |
| N20-405 | Nivo/Ipi/PEM/CBDCA q3w (1c eyes) | |
| N20-405 | Nivo/Ipi/PEM/CDDP q3w (1c eye) | |
| N20-404 | Nivo/Ipi/PTX/CBDCA q3w (1c eye) | |
| N20-304 | Nivo/PEM/CBDCA q3w (2c eyes) | |
| N23-301 | Nivo/PEM/CDDP triweekly (preoperatively) (non-squamous cell carcinoma) | |
| N20-304 | Nivo/PEM/CDDP q3w (2c eyes) | |
| N20-303 | Nivo/PTX/CBDCA q3w (2c eyes) | |
| N23-301 | Nivo/PTX/CBDCA triweekly (preoperatively) | |
| N18-102 | Nivolumab biweekly (NSCLC) | |
| N20-102 | Nivolumab (480mg/b) q4w (NSCLC) | |
| P15-102 | PEM (500) triweekly | |
| P15-203 | PEM/CBDCA triweekly | |
| P15-206 | PEM/CDDP triweekly | |
| P17-102 | Pembrolizumab triweekly (NSCLC) | |
| P20-101 | Pembrolizumab (400mg/b) q6w (NSCLC) | |
| P18-302 | Pembrolizumab/CBDCA/nabPTX(d1,8,15)q3w | |
| P18-303 | Pembrolizumab/CBDCA/PEMq3w1-4c | |
| P18-302 | Pembrolizumab/CBDCA/PTX triweekly | |
| P18-304 | Pembrolizumab/CDDP/PEMq3w1-4c | |
| P18-202 | Pembrolizumab/PEM q3w maintenance therapy | |
| P16-202 | PTX(70)(d1,8,15)/CBDCA(6) monthly | |
| P16-202 | PTX/CBDCA triweekly (lung cancer) | |
| P16-201 | PTX/CBDCA Weekly | |
| R18-102 | Ram triweekly | |
| D16-202 | Ram/DTX triweekly | |
| E20-201 | Ram/Erlotinib (d1-14) biweekly | |
| B17-202 | S1(d1-14)/Bev triweekly (lung cancer) | |
| C15-202 | S1 (d1-14)/CBDCA triweekly | |
| T23-101 | T-DXd triweekly (lung cancer) | |
| T15-101 | Topotecan(d1-5) triweekly | |
| T23-401 | Treme/Durva/nabPTX(d1,8,15)･CBDCA q3w 1-4c | |
| T23-401 | Treme/Durva/PEM/CBDCA triweekly 1-4c | |
| T23-401 | Treme/Durva/PEM/CDDP triweekly 1-4c | |
| T23-201 | Treme/Durva q4w maintenance 2nd time | |
| T23-301 | Treme/Durva/PEM q4w 2nd maintenance | |
| V15-101 | VNR weekly (lung cancer) | |
| V15-202 | VNR（d1,8）/CBDCA triweekly | |
| V15-204 | VNR（d1,8）/CDDP triweekly | |
| V15-201 | VNR（d1,8）/CDDP（d1,8） triweekly | |
| P15-204 | Radiation every 3 weeks S1/CDDP | |
| V15-202 | Radiation VNR (d1,8)/CDDP (d1,8) triweekly |
Cancer chemotherapy regimen breast cancer
Update date and time: March 12, 2024
| A15-101 | Abraxane triweekly | |
| A15-201 | AC (breast cancer) | |
| A19-201 | Atezo(d1,15)/nabPTX(d1,8,15) monthly | |
| F15-201 | CMF (breast cancer) | |
| CPT16-101 | CPT-11 weekly (breast cancer) | |
| A15-202 | dose-dense AC (breast cancer) | |
| E22-201 | dose-dense EC (breast cancer) | |
| D16-101 | DTX triweekly (breast cancer) | |
| D16-201 | DTX/CPA triweekly (breast cancer) | |
| E15-202 | EC triweekly (breast cancer) | |
| E15-101 | Eribulin (d1,8) triweekly | |
| F15-301 | FEC (breast cancer) | |
| G15-101 | GEM (d1,8) triweekly (breast cancer) | |
| F15-301 | iv CMF (breast cancer) | |
| P22-301 | Pembro/ADM(60)/CPA(600) triweekly | |
| P22-301 | Pembro/EPI(90)/CPA(600) triweekly | |
| P22-301 | Pembro/wPTX(80)/CBDCA (AUC5) triweekly | |
| P21-301 | Pembro/GEM/CBDCA（AUC=2） triweekly | |
| P22-101 | Pembrolizumab (200) q3w (breast cancer) | |
| P22-101 | Pembrolizumab (400) q6w (breast cancer) | |
| P21-201 | Pembrolizumab/nab-PTX(d1,8) triweekly | |
| P21-201 | Pembrolizumab/PTX(d1,8) triweekly | |
| P18-201 | PER/Tmab triweekly (first course) | |
| P18-201 | PER/Tmab triweekly (after the 2nd course) | |
| P18-301 | PER/Tmab/DTX triweekly (first course) | |
| P18-301 | PER/Tmab/DTX triweekly (after 2nd course) | |
| P19-401 | PER/Tmab/DTX/CBDCA triweekly (first course) | |
| P19-401 | PER/Tmab/DTX/CBDCA triweekly (after the 2nd course) | |
| P18-301 | PER/Tmab/PTX triweekly (first course) | |
| P18-301 | PER/Tmab/PTX triweekly (after 2nd course) | |
| P23-201 | PHESGO triweekly (1st course) | |
| P23-201 | PHESGO triweekly (2nd course onwards) | |
| P23-301 | PHESGO/DTX triweekly (1st course) | |
| P23-301 | PHESGO/DTX triweekly (2nd course onwards) | |
| P23-401 | PHESGO/DTX/CBDCA triweekly (1st course) | |
| P23-401 | PHESGO/DTX/CBDCA triweekly (2nd course onwards) | |
| P23-301 | PHESGO/nabPTX triweekly (1st course) | |
| P23-301 | PHESGO/nabPTX triweekly (2nd course onwards) | |
| P23-301 | PHESGO/PTX triweekly (1st course) | |
| P23-301 | PHESGO/PTX triweekly (2nd course onwards) | |
| P23-302 | PHESGO/VNR(d1,8) triweekly (1st course) | |
| P23-302 | PHESGO/VNR(d1,8) triweekly (2nd course onwards) | |
| P16-101 | PTX weekly (breast cancer) | |
| P16-201 | PTX（d1,8,15）/BV（d1,15） monthly | |
| T15-101 | T-DM1 triweekly | |
| T20-101 | T-DXd triweekly | |
| T20-101 | Tmab triweekly (first time) | |
| T20-101 | Tmab triweekly (second time onwards) | |
| T20-101 | Tmab weekly (1st time) | |
| T20-101 | Tmab weekly (after the second time) | |
| T20-201 | Tmab/Abraxane triweekly (1st time) | |
| T20-201 | Tmab/Abraxane triweekly (after the second time) | |
| T20-201 | Tmab/CPT-11 weekly (1st time) | |
| T20-201 | Tmab/CPT-11 weekly (after the second time) | |
| T20-201 | Tmab/DTX triweekly (1st time) | |
| T20-201 | Tmab/DTX triweekly (after the second time) | |
| T20-301 | Tmab/DTX/CBDCA triweekly (first course) | |
| T20-301 | Tmab/DTX/CBDCA triweekly (after the 2nd course) | |
| T20-301 | Tmab/DTX/CPA triweekly (first course) | |
| T20-301 | Tmab/DTX/CPA triweekly (after the 2nd course) | |
| T20-201 | Tmab/Eribulin (d1,8) triweekly (first course) | |
| T20-201 | Tmab/Eribulin (d1,8) triweekly (after the 2nd course) | |
| T20-201 | Tmab/PTX weekly (1st time) | |
| T20-201 | Tmab/PTX weekly (after the second time) | |
| T20-301 | Tmab/PTX(d1, 8)/GEM(d1, 8) triweekly (first course) | |
| T20-301 | Tmab/PTX(d1, 8)/GEM(d1, 8) triweekly (after the 2nd course) | |
| T20-301 | Tmab/PTX/CBDCA triweekly (first course) | |
| T20-301 | Tmab/PTX/CBDCA triweekly (after the 2nd course) | |
| T20-201 | Tmab/VNR (d1, 8) triweekly (first course) | |
| T20-201 | Tmab/VNR (d1, 8) triweekly (after the 2nd course) | |
| V15-101 | VNR weekly (breast cancer) | |
| T20-201 | weekly Tmab/Abraxane (after the second time) | |
Cancer chemotherapy regimen gastric cancer
Last updated: April 4, 2024
| P15-203 | Every 5 weeks S1/CDDP | |
|---|---|---|
| A17-101 | Abraxane weekly (stomach cancer) | |
| CPT15-102 | CPT-11 biweekly (gastric cancer) | |
| CPT15-202 | CPT-11(d1, 15)/CDDP monthly (gastric cancer) | |
| CPT15-202 | CPT-11/CDDP biweekly | |
| D16-101 | DTX weekly (stomach cancer) | |
| F17-203 | FOLFOX6 (gastric cancer) | |
| F21-201 | 5-FU/l-LV+PTX monthly | |
| O15-202 | G-SOX (100mg/m2) triweekly | |
| O15-202 | G-SOX (130mg/m2) triweekly | |
| O15-202 | G-XELOX triweekly | |
| H18-201 | HER/CAP (d1-14) triweekly (1st time) | |
| H18-201 | HER/CAP (d1-14) triweekly (after the second time) | |
| O18-301 | HER/G-SOX triweekly (first course) | |
| O18-301 | HER/G-SOX triweekly (after 2nd course) | |
| O18-301 | HER/XELOX triweekly (first course) | |
| O18-301 | HER/XELOX triweekly (after the 2nd course) | |
| H18-302 | HER/XP (first time) | |
| H18-302 | HER/XP (2nd time onwards) | |
| T20-403 | mFOLFOX6+Tmab biweekly (1c eye) | |
| T20-403 | mFOLFOX6+Tmab biweekly (after 2c) | |
| P18-203 | nabPTX(d1,8,15)/Ram(d1,15) monthly | |
| N21-303 | Nivo/SOX triweekly | |
| N21-303 | Nivo/XELOX triweekly | |
| N21-303 | Nivo+mFOLFOX6 biweekly | |
| N18-102 | Nivolumab biweekly (gastric cancer) | |
| N20-102 | Nivolumab (480mg/b) q4w (gastric cancer) | |
| P16-101 | PTX weekly (gastric cancer) | |
| R16-202 | Ram(d1,15)/PTX(d1,8,15) monthly | |
| R21-202 | Ram/CPT-11 biweekly | |
| R15-101 | Ramucirumab biweekly | |
| D16-201 | S1(d1-14)/DTX triweekly | |
| T20-102 | T-DXd triweekly (gastric cancer) | |
| T20-201 | Tmab/CAP (d1-14) triweekly (first time) | |
| T20-201 | Tmab/CAP (d1-14) triweekly (after 2nd time) | |
| O20-303 | Tmab/G-SOX triweekly (first course) | |
| O20-303 | Tmab/G-SOX triweekly (after 2nd course) | |
| P18-305 | Tmab/SP (first course) | |
| P18-305 | Tmab/SP (after 2nd course) | |
| O20-303 | Tmab/XELOX triweekly (first course) | |
| O20-303 | Tmab/XELOX triweekly (after 2nd course) | |
| T20-304 | Tmab/XP (first time) | |
| T20-304 | Tmab/XP (after the second time) |
Cancer chemotherapy regimen Esophageal cancer
Last updated: April 4, 2024
| F16-204 | CDGP/5FU (96 hours) monthly (infuser) | |
| F16-303 | DCF monthly (Infuser) | |
| F21-303 | DCF monthly (infuser) (with line keep) | |
| F22-301 | DCF(70-70-3750) triweekly (Tunai) | |
| D16-101 | DTX triweekly (esophageal cancer) | |
| P21-201 | FP (1000/75) (5-FU: 96 hours, infuser) monthly | |
| P21-201 | FP (1000/75) (5-FU: 96 hours, infusion pump) monthly | |
| F17-202 | FP (70-700) radiation | |
| F17-202 | high dose FP | |
| F15-203 | high dose FP (5-FU: 120 hours, infuser) | |
| F15-203 | high dose FP (5-FU: 96 hours, infuser) monthly | |
| N22-201 | Nivo(d1,22)/Ipi(d1) q6w (esophageal cancer) | |
| N22-301 | Nivo(day1,15)/FP monthly (esophageal cancer) | |
| N20-102 | Nivolumab biweekly (esophageal cancer) | |
| N20-102 | Nivolumab (480mg/b) q4w (esophageal cancer) | |
| P21-101 | Pembrolizumab triweekly (esophageal cancer) | |
| P21-101 | Pembrolizumab (400mg/b) q6w (esophageal cancer) | |
| P21-301 | Pembrolizumab/FP triweekly (esophageal cancer) | |
| P16-101 | PTX weekly (esophageal cancer) |
Cancer chemotherapy regimen colon cancer
Last updated: April 4, 2024
| F18-302 | Aflibercept/FOLFIRI biweekly | |
| F17-305 | Bev(10mg/kg)/FOLFOX6 biweekly | |
| F17-303 | Bev(5mg/kg)/FOLFIRI biweekly | |
| F17-305 | Bev(5mg/kg)/FOLFOX6 biweekly | |
| CPT15-303 | Bev(5mg/kg)/IRIS | |
| B15-202 | Bev(d1、15) /TAS-102(d1-5、8-12) monthly | |
| C15-203 | Bev/Cape(d1-14) triweekly | |
| O17-403 | Bev/FOLFOXIRI | |
| O15-303 | Bev/SOX triweekly | |
| O15-303 | Bev/XELOX triweekly | |
| Cm15-101 | Cmab weekly (first time) | |
| Cm15-101 | Cmab weekly (after the second time) | |
| C15-204 | Cmab weekly/CPT-11 biweekly (first course) | |
| C15-204 | Cmab weekly/CPT-11 biweekly (after the 2nd course) | |
| F17-303 | Cmab(d1, 8)/FOLFIRI (first course) | |
| F17-303 | Cmab(d1, 8)/FOLFIRI (after the 2nd course) | |
| F17-303 | Cmab(d1, 8)/FOLFOX6 (first course) | |
| F17-303 | Cmab(d1, 8)/FOLFOX6 (after the 2nd course) | |
| C21-301 | C-mab+encorafenib+binimetinib (first time) | |
| C21-301 | C-mab+encorafenib+binimetinib (2nd time onwards) | |
| CPT15-102 | CPT-11 biweekly (colorectal cancer) | |
| F17-202 | FOLFIRI | |
| F17-202 | FOLFOX6 | |
| O17-302 | FOLFOXIRI | |
| N20-102 | Nivo (480mg, Nivo/Ipi maintenance q4w, (MSI-H colorectal) | |
| N20-102 | Nivo(Nivo/Ipi maintenance q2w(MSI-High colon/rectum) | |
| N20-203 | Nivo/Ipi triweekly (MSI-High colorectal cancer) | |
| N20-102 | Nivolumab q2w (MSI-High/Colorectal cancer) | |
| Pm16-101 | Pmab biweekly | |
| Pm15-201 | Pmab/CPT-11 biweekly | |
| F17-302 | Pmab/FOLFIRI biweekly | |
| F17-302 | Pmab/FOLFOX6 biweekly | |
| F17-303 | Ram/FOLFIRI biweekly | |
| B15-202 | S1(d1-28) / Bev(d1,15,29) every 6 weeks | |
| B17-303 | SIRB triweekly | |
| O15-202 | SOX | |
| F19-101 | WHF therapy ia (infuser pump) weekly | |
| CPT18-303 | XELIRI + Bev triweekly | |
| O15-202 | XELOX |
Cancer chemotherapy regimen Bile/liver/pancreatic cancer
Last updated: April 4, 2024
| A20-201 | Atezolizumab/Bev q3w (hepatocellular carcinoma) | |
| D23-301 | Durva(d1)/GC(d1,8) triweekly (BW＞30kg) | |
| D23-301 | Durva(d1)/GC(d1,8) triweekly (BW≦30kg) | |
| D23-101 | Durva (Treme/Durva) 2nd course or later (BW＞30kg)q4w | |
| D23-101 | Durva (Treme/Durva) 2nd course or later (BW≦30kg)q4w | |
| D23-101 | Durvalumab maintenance monthly (BW＞30kg) (Biliary tract cancer) | |
| D23-101 | Durvalumab maintenance monthly (BW≦30kg) (Biliary tract cancer) | |
| F17-302 | FOLFIRINOX | |
| G15-101 | GEM biweekly (pancreatic cancer) | |
| G15-101 | GEM (d1,8) triweekly (biliary tract cancer) | |
| G15-101 | GEM(d1,8) triweekly (pancreatic cancer) | |
| G15-201 | GEM（d1,8）/CDDP（d1,8）triweekly | |
| G20-201 | GEM (d1,8) + S-1 (d1-14) triweekly (pancreatic cancer) | |
| G15-101 | GEM (d1,8,15) monthly (biliary tract cancer) | |
| G15-101 | GEM (d1,8,15) monthly (pancreatic cancer) | |
| F17-303 | ｍFOLFIRINOX | |
| G15-204 | nabPTX（d1,8,15）/GEM（d1,8,15） | |
| I20-202 | nal-IRI/5-FU/l-LV biweekly | |
| T23-201 | Tremelimumab/Durva 1st course (BW＞30kg)monthly | |
| T23-201 | Tremelimumab/Durva 1st course (BW≦30kg)monthly | |
| R19-102 | Ram biweekly (hepatocellular carcinoma) |
Cancer chemotherapy regimen Gynecologic cancer
Update date and time: November 24, 2023
| A15-101 | ACTD biweekly | |
| A15-203 | ADM/CDDP triweekly | |
| B15-305 | BEP therapy (d1-5,9,16) (ovarian germ cell tumor) | |
| B20-302 | Bev biweekly/CBDCA/PLD monthly | |
| B21-202 | Bev biweekly/PLD monthly | |
| B15-102 | Bev triweekly (gynecologic cancer) | |
| B15-202 | Bev triweekly/PLD monthly 1st course | |
| B15-202 | Bev triweekly/PLD monthly 2nd course | |
| B15-202 | Bev triweekly/PLD monthly 3rd course | |
| B16-203 | Bev triweekly/PTX weekly Course 1 | |
| B16-203 | Bev triweekly/PTX weekly 2nd course | |
| B16-203 | Bev triweekly/PTX weekly 3rd course | |
| D19-302 | Bev/DTX/CBDCA triweekly (ovarian cancer) | |
| B17-202 | Bev/GEM (d1,8) triweekly | |
| G15-302 | Bev/GEM(d1,8)/CBDCA tri (gynecologic cancer) | |
| B22-202 | Bev/Olaparib triweekly (ovarian cancer) | |
| P16-302 | Bev/PTX/CBDCA triweekly (cervical cancer) | |
| P16-302 | Bev/PTX/CBDCA triweekly (ovarian cancer) | |
| B18-302 | Bev/PTX/topotecan(d1-3) triweekly | |
| B15-202 | Bev/Topotecan(d1-5) triweekly | |
| C15-101 | CBDCA weekly (gynecologic cancer) | |
| P15-102 | CDDP weekly (for CCRT) | |
| C15-101 | CDGP monthly | |
| C23-101 | Cemiplimab triweekly | |
| CPT15-101 | CPT-11 weekly (gynecologic cancer) | |
| CPT15-201 | CPT-11(d1,8)/CDGP monthly | |
| C15-203 | CPT-11(d1,8,15)/CDDPmonthly (gynecologic cancer) | |
| CPT15-202 | CPT-11(d1,8,15)/CDGP monthly | |
| P16-202 | divided weekly TC (AUC=2) | |
| P16-202 | dose-dense TC | |
| D16-101 | DTX triweekly (gynecologic cancer) | |
| D16-201 | DTX (d8)/GEM (d1,8) triweekly (gynecologic cancer) | |
| D16-201 | DTX/CBDCA triweekly (gynecologic cancer) | |
| M15-501 | EMA/CO biweekly | |
| F17-201 | FA biweekly | |
| G15-201 | GEM（d1,8）/CBDCA（AUC=4） triweekly | |
| G15-101 | GEM (d1,8,15) monthly (ovarian cancer) | |
| I18-101 | IFM triweekly | |
| I18-201 | IFM/PTX triweekly | |
| M14-101 | MTX (d1-5) im biweekly | |
| M14-101 | MTX im weekly (ectopic pregnancy) | |
| N15-101 | Nogitecan(d1-5) triweekly | |
| A15-101 | PLD monthly（90mg/body以下） | |
| A15-101 | PLD monthly（90mg/body以上） | |
| P22-201 | Pembro/Bev triweekly maintenance therapy | |
| P22-401 | Pembro/Bev/PTX/CBDCA triweekly | |
| P22-401 | Pembro/Bev/PTX/CDDP triweekly | |
| P21-201 | Pembro/Lenvatinib q3week (uterine cancer) | |
| P21-201 | Pembro/Lenvatinib q6week (uterine cancer) | |
| P22-301 | Pembro/PTX/CBDCA triweekly | |
| P22-301 | Pembro/PTX/CDDP triweekly | |
| P22-101 | Pembrolizumab triweekly maintenance therapy (cervical cancer) | |
| A15-201 | PLD/CBDCA monthly | |
| P16-102 | PTX weekly (gynecologic cancer) | |
| P16-202 | PTX/CBDCA triweekly (gynecologic cancer) | |
| P16-203 | PTX/CDDP triweekly (gynecologic cancer) | |
| P16-303 | TP/TE | |
| P16-202 | weekly TC (AUC=6) |
Cancer chemotherapy regimen Urologic/germinoma
Last updated: April 4, 2024
| A20-201 | Axitinib daily/Avelumab biweekly | |
| P19-201 | Axitinib daily/Pembrolizumab triweekly | |
| P20-201 | Axitinib daily/Pembrolizumab(400mg/b) q6w | |
| D16-201 | DTX(d8)/GEM(d1,8) tri (urothelial carcinoma) | |
| E21-101 | Enfortumab vedotin q4week (urothelial carcinoma) | |
| G15-202 | GC therapy (d1,8,15) | |
| P15-203 | GC therapy (d2) | |
| G15-202 | GEM（d1,8,15）/CBDCA（d1） monthly | |
| C14-202 | GEM(d1,8,15)/CBDCA(d2)monthly | |
| E15-402 | mitotane daily / EDP monthly | |
| M15-403 | M-VAC therapy (afternoon start) | |
| N18-202 | Nivo (Nivo/Ipi maintenance therapy biweekly (renal cell carcinoma) | |
| N20-102 | Nivo (Nivo/Ipi maintenance therapy 480mg/b) q4w (renal cell carcinoma) | |
| N18-203 | Nivo/Ipi triweekly (renal cell carcinoma) | |
| N18-102 | Nivolumab biweekly (renal cell carcinoma) | |
| N20-102 | Nivolumab (480mg/b) q4w (renal cell carcinoma) | |
| P17-101 | Pembrolizumab tri (urothelial carcinoma) | |
| P20-101 | Pembrolizumab (400mg/b) q6w (urothelial carcinoma) | |
| C15-201 | PSL daily/Cabazitaxel triweekly | |
| D18-201 | PSL(d1-7)/DTX triweekly_(morning start) | |
| P16-202 | PTX/CBDCA triweekly (urothelial carcinoma) |
Cancer chemotherapy regimen Hematopoietic malignancies
Update date and time: March 12, 2024
| B18-401 | ABVD (outpatient) | |
| A20-301 | A-CHP | |
| A15-101 | AzaC (d1-7)_monthly (outpatient) | |
| A19-101 | AzaC subcutaneous injection (d1-7)_monthly (outpatient) | |
| B22-101 | Blinatumomab for home pump 28μg/d 72hr with Dex | |
| B22-101 | Blinatumomab for home pump 28μg/d 96hr with Dex | |
| B22-101 | Blinatumomab for home pump 28μg/d 72hr No Dex | |
| B22-101 | Blinatumomab for home pump 28μg/d 96hr No Dex | |
| B22-101 | Blinatumomab for home pump 15μg/㎡ 72h with Dex | |
| B22-101 | Blinatumomab for home pump 15μg/㎡ 96h with Dex | |
| B22-101 | Blinatumomab for home pump 15μg/㎡ 72h No Dex | |
| B22-101 | Blinatumomab for home pump 15μg/㎡ 96h No Dex | |
| B22-101 | Blinatumomab for home pump 9μg/d 72hr with Dex | |
| B22-101 | Blinatumomab for home pump 9μg/d 96hr with Dex | |
| B22-101 | Blinatumomab for home pump 9μg/d 72hr No Dex | |
| B22-101 | Blinatumomab for home pump 9μg/d 96hr No Dex | |
| B22-101 | Blinatumomab for home pump 5μg/㎡ 72hr with Dex | |
| B22-101 | Blinatumomab for home pump 5μg/㎡ 96hr with Dex | |
| B22-101 | Blinatumomab for home pump 5μg/㎡ 72hr No Dex | |
| B22-101 | Blinatumomab for home pump 5μg/㎡ 96hr No Dex | |
| B17-101 | Brentuximab triweekly (BW＞87) | |
| B17-101 | Brentuximab triweekly (BW≦87) | |
| A15-301 | CHOP (Outpatient) | |
| CPT15-101 | CPT-11(d1-3) weekly | |
| D23-101 | Darinaparsin triweekly | |
| D21-203 | DBdsc therapy cycle 1-3 | |
| D21-203 | DBdsc therapy cycles 4-8 | |
| D21-203 | DBdsc therapy cycle 9 and beyond | |
| D18-202 | DBd therapy triweekly cycle 1 | |
| D18-202 | DBd therapy triweekly cycle 2-3 | |
| D18-202 | DBd therapy triweekly cycles 4-8 | |
| D17-201 | DBd therapy monthly Cycle 9 or later | |
| D22-301 | DCyBorD Therapy (iv) Cycle 1-2 | |
| D22-301 | DCyBorD therapy (iv) cycles 3-6 | |
| D22-301 | DCyBorD therapy (po) cycle 1-2 | |
| D22-301 | DCyBorD therapy (po) cycles 3-6 | |
| D22-101 | DCyBorD therapy cycle 7 and beyond | |
| D21-203 | DKdsc therapy Cycle 1 | |
| D21-203 | DKdsc therapy Cycle 2 | |
| D21-203 | DKdsc therapy cycle 3-6 | |
| D21-203 | DKdsc therapy Cycle 7 or later | |
| D20-201 | DKd therapy monthly Cycle 1 | |
| D20-201 | DKd therapy monthly Cycle 2 | |
| D20-201 | DKd therapy monthly cycle 3-6 | |
| D20-201 | DKd therapy monthly Cycle 7- | |
| D21-203 | DKdsc therapy (*K once a week) Cycle 1 | |
| D21-203 | DKdsc therapy (*K once a week) Cycle 2 | |
| D21-203 | DKdsc therapy (*K once a week) Cycles 3-6 | |
| D21-203 | DKdsc therapy (*K once a week) from cycle 7 onwards | |
| D17-201 | DLd therapy monthly Cycle 1 | |
| D17-201 | DLd therapy monthly Cycle 2 | |
| D17-201 | DLd therapy monthly cycle 3-6 | |
| D17-201 | DLd therapy monthly Cycle 7 or later | |
| D21-203 | DLdsc therapy cycle 1-2 | |
| D21-203 | DLdsc therapy cycle 3-6 | |
| D21-203 | DLdsc therapy cycle 7 and beyond | |
| D23-201 | DPdsc therapy cycle 1-2 | |
| D23-201 | DPdsc therapy cycle 3-6 | |
| D23-201 | DPdsc therapy Cycle 7 or later | |
| D20-401 | D-VMP Therapy Cycle 1 | |
| D20-401 | D-VMP Therapy Cycle 2-9 | |
| D20-401 | D-VMP therapy Cycle 10 and beyond | |
| D21-403 | D-VMPsc therapy cycle 1 | |
| D21-403 | D-VMPsc therapy cycles 2-9 | |
| D21-403 | D-VMPsc therapy cycle 10 and beyond | |
| E19-301 | EPd therapy (1st-2nd course) | |
| E19-301 | EPd therapy (after the 3rd course) | |
| E16-301 | ERd therapy (1st course) | |
| E16-301 | ERd therapy (2nd course) | |
| E16-301 | ERd therapy (after the 3rd course) | |
| G15-301 | GCOP (1000) (outpatient) | |
| G15-301 | GCOP (750) (outpatient) | |
| G15-301 | GCOP (875) (outpatient) | |
| G15-101 | GDP_Over 70 (outpatient) | |
| I18-101 | Inotuzumab ozogamicin (until remission) | |
| I18-101 | Inotuzumab ozogamicin (post-remission) | |
| I20-302 | IPd therapy (BW≤85) (1st course) | |
| I20-302 | IPd therapy (BW ≤ 85) (after the 2nd course) | |
| I20-302 | IPd therapy (BW86-100) (1st course) | |
| I20-302 | IPd therapy (BW86-100) (after 2nd course) | |
| I22-201 | Isad therapy monthly cycle 1 (BW ≤ 85) | |
| I22-201 | Isad therapy monthly cycle 1 (BW86-100) | |
| I22-201 | Isad therapy monthly cycle 2 or later (BW ≤ 85) | |
| I22-201 | Isad therapy monthly cycle 2 or later (BW86-100) | |
| I22-301 | IsaKd therapy monthly cycle 1 (BW ≤ 85) | |
| I22-301 | IsaKd therapy monthly cycle 1 (BW86-100) | |
| I22-301 | IsaKd therapy monthly Cycle 2 or later (BW ≤ 85) | |
| I22-301 | IsaKd therapy monthly Cycle 2 or later (BW86-100) | |
| C19-201 | Kd weekly (first course) | |
| C19-201 | Kd weekly (after the 2nd course) | |
| C18-201 | Kd therapy (1st course) | |
| C18-201 | Kd therapy (after the 2nd course) | |
| C18-301 | KRd therapy (1st course) | |
| C18-301 | KRd therapy (2nd to 12th course) | |
| C18-301 | KRd therapy (13th to 18th course) | |
| M15-101 | Mogamulizumab weekly | |
| N18-102 | Nivolumab biweekly (Hodgkin's lymphoma) | |
| O18-204 | Obi-Bendamustine C2-6 | |
| O18-402 | Obi-CHOP C2-6 | |
| O18-102 | Obi-CHOP C7-8 | |
| O18-302 | Obi-CVP C2-8 | |
| O18-102 | Obinutuzumab (maintenance/monotherapy) | |
| O24-201 | Obi(d1,2,8,15)-Acalabrutinib q4w C2 | |
| O24-201 | Obi-Acalabrutinib q4w C3-7 | |
| A17-101 | PLD biweekly | |
| P21-304 | Pola-BR (BW＜85kg) C2-6 | |
| P21-304 | Pola-BR (BW≧85kg) C2-6 | |
| P22-401 | Pola-R-CHP (BW≧85kg) triweekly C2-6 (outpatient) | |
| P22-401 | Pola-R-CHP (BW＜85kg) triweekly C2-6 (outpatient) | |
| P22-101 | Pola-R-CHP triweekly C7-8 (outpatient) | |
| M15-401 | POMP therapy (first year) | |
| R20-201 | R2 (cycle 1) | |
| R20-201 | R2 (cycle 2-5) | |
| R19-203 | R-Bendamustine (Outpatient) | |
| R14-402 | R-THPCOP (outpatient) | |
| C19-301 | RCD (CPA div) | |
| R19-301 | RCD（CPA po） | |
| R19-401 | R-CHOP (Outpatient) | |
| R19-301 | R-GCD (outpatient) triweekly | |
| R20-401 | R-GCOP (1000) (outpatient) | |
| R20-401 | R-GCOP (750) (outpatient) | |
| R19-201 | R-GDP 70+ (outpatient) triweekly | |
| R19-302 | R-GDP (Foreign) triweekly | |
| R19-101 | Rituximab (outpatient) | |
| R19-401 | R-mini CHOP (Outpatient) | |
| C23-201 | VEN＋low dose Ara-C subcutaneous injection (d1-10) monthly | |
| A15-102 | Arsenite after remission | |
| A15-102 | Arsenite Remission induction |
Cancer chemotherapy regimen Head and neck cancer
Last updated: April 4, 2024
| C15-203 | CBDCA/5-FU triweekly | |
| P18-102 | CDDP（40）+RT weekly | |
| Cm15-101 | Cmab weekly with radiation (first time) | |
| Cm15-101 | Cmab weekly combined with radiation (2nd time onwards) | |
| C15-304 | Cmab(d1,8,15)/CBDCA･5-FU triweekly(initial course) | |
| C15-304 | Cmab(d1,8,15)/CBDCA/5-FU triweekly(2nd and subsequent doses) | |
| C15-305 | Cmab/FP triweekly (first course) | |
| C15-305 | Cmab/FP triweekly (2nd course onwards) | |
| C16-201 | Cmab/PTX weekly (1st course) | |
| C16-201 | Cmab/PTX weekly (after 2nd course) | |
| F15-205 | FP (70-700) (5-FU, 96 hours, infuser) (head and neck)) | |
| N18-102 | Nivolumab biweekly (head and neck cancer) | |
| N20-102 | Nivolumab (480mg/b) q4w (head and neck cancer) | |
| P19-101 | Pembrolizumab triweekly (head and neck cancer) | |
| P20-101 | Pembrolizumab (400mg/b) q6w (head and neck cancer) | |
| P19-304 | Pembrolizumab/CBDCA/5-FU triweekly | |
| P19-304 | Pembrolizumab/FP triweekly | |
| P16-101 | PTX weekly (head and neck cancer) |
Cancer chemotherapy regimen skin cancer
Update date and time: November 29, 2023
| D15-101 | DTIC（250mg/m2）（d1-5） monthly | |
| D16-101 | DTX triweekly (Paget's disease) | |
| D16-101 | DTX weekly (Paget's disease) | |
| I18-101 | Ipilimumab triweekly | |
| N18-203 | Nivo/Ipi triweekly (malignant melanoma) | |
| N23-101 | Nivolumab(480mg/b) q4w (malignant melanoma) | |
| N18-102 | Nivolumab biweekly (malignant melanoma) | |
| P23-101 | Pembrolizumab (400mg/b) q6w (malignant melanoma) | |
| P19-101 | Pembrolizumab triweekly (malignant melanoma) | |
| P16-101 | PTX weekly (Paget's disease) |
Cancer chemotherapy regimen cancer of unknown primary
Update date: May 19, 2022
| G15-201 | GEM (d1,8)/CPT-11(d1,8) triweekly |
To doctors at regional medical institutions
Various workshops are held with the aim of deepening cooperation between out-of-hospital pharmacies and hospitals and sharing information to ensure the safety of drug therapy. In addition, we will strengthen drug-drug collaboration by sharing information using medication information sheets (tracing reports). When you introduce a patient, please instruct them to carry a medicine notebook or use an electronic medicine notebook.
About the use of medical records
About the use of medical records
Notice regarding implementation of clinical research for patients undergoing medical examination at our hospital
Currently, the Department of Pharmacy is conducting the following clinical research.
In this research, we will use the data (information) obtained from the patient's daily clinical practice.
If you object to the use of your data for this research, you can stop using the information at any time. If you would like to know more about the research plan or content, if you have any objections to the use of your data in this research, or if you have any other questions, please contact us at the contact information below. .
| Research subject | Description (PDF) |
| Research on the usefulness of pharmacist-assisted test input support for early detection of adverse events caused by immune checkpoint inhibitors | |
|---|---|
| Risk factor analysis of neutropenia induced by GEM + nab-PTX therapy in pancreatic cancer patients and its relationship with prognosis | |
| Efforts regarding proper use based on pharmacist intervention cases in the psychiatric liaison team | |
| Effects of long-term administration of voriconazole injection on renal function in patients with renal dysfunction | |
| Risk factor search for adverse events of PARP inhibitors in ovarian cancer patients and blood concentration analysis | |
| Investigation on the time to start pralidoxime administration in organophosphate poisoning and its effect on recovery of cholinesterase level | |
| Investigation of administration of rivaroxaban for Trousseau syndrome in diabetic patients | |
| Fact-finding survey of therapeutic agents for coronary artery disease in acute care hospitals | |
| Fact-finding survey on the combined use of lipid emulsions during total parenteral nutrition in acute care hospitals | |
| Fact-finding survey of hypertriglyceridemia caused by administration of propofol in ICU | |
| A study on the significance of dose reduction to avoid treatment discontinuation due to side effects of lenvatinib for hepatocellular carcinoma | |
| Fact-finding survey on the use of infusion routes for venous catheter infections, etc. | |
| Examination of pharmacological problems in post-ICU patients | |
| Investigation on the usefulness and safety of adrenaline administration for the prevention of anaphylactic reactions with viper antitoxin | |
| Pharmaceutical management of SGLT2 inhibitors in perioperative support centers | |
| Development of skin disorders caused by apalutamide, a therapeutic drug for prostate cancer, and investigation of risk factors in clinical practice | |
| Analysis of pharmacist work in prehospital preparation center and verification of its usefulness | |
| Fact-finding survey of patients transported by ambulance for type 2 diabetic ketoacidosis | |
| A multicenter study on the effect of bevacizumab pretreatment on the development of proteinuria after ramucirumab administration | |
| A study on the usefulness of outpatient pharmacist in pharmacotherapy for urinary cancer | |
| Effect of Oral Diabetes Agent SGLT2 Inhibitor on Postoperative Acidosis | |
| Study on risk factors for proteinuria caused by oral angiogenesis inhibitors | |
| Whole blood concentration prediction of immunosuppressant tacrolimus considering erythrocyte count fluctuation in hematopoietic stem cell transplantation | |
| Exploring factors that affect hemoglobin level fluctuations in allogeneic hematopoietic stem cell transplant patients | |
| Pharmacokinetic study of ceftriaxone in dialysis patients | |
| Relationship between blood 25-hydroxyvitamin D concentration and severity of novel coronavirus infection (COVID-19) | |
| Examination of risk factors for lymphopenia in bendamustine-treated patients | |
| Pharmacokinetic study of remdesivir in severe COVID-19 patients | |
| Pharmacokinetic study of favipiravir in severe COVID-19 patients | |
| Construction of treatment-related database of vancomycin-administered patients, extraction of influencing factors on pharmacokinetics using the database, and expansion of optimization of population parameters | |
| Population pharmacokinetic model analysis of methotrexate in hyper-CVAD/MA therapy | |
| A retrospective study on the effect of rikkunshito on malnutrition after gastrectomy | |
| A Clinical Investigation on Factors Affecting Myelosuppression with Lenalidomide and Dexamethasone Combination Therapy | |
| Examination of MSI-High expression status and efficacy and safety of pembrolizumab administration in Japanese patients with solid tumors | |
| Adverse event evaluation of enzalutamide dose escalation in castration-resistant prostate cancer | |
| PK/PD model analysis of neutropenia following docetaxel plus ramucirumab combination therapy in patients with non-small cell lung cancer | |
| Blood concentration measurement and kinetic analysis for suspected cases of drug poisoning and evaluation of its usefulness | |
| Evaluation of the effect of combined lipid emulsion on liver function during total parenteral nutrition in an acute care hospital | |
| Use and safety survey of a novel hypnotic orexin receptor antagonist, suvorexant | |
| Efficacy and safety evaluation of dose-dense TC therapy in patients with diabetes and ovarian cancer | |
| Verification of aroma treatment effects of complementary and alternative medicine (CAM) as integrative medicine in palliative care | |
| Evaluation of Fall Risk of Suvorexant and Other Sedative Hypnotics | |
| Risk factor analysis for bleeding complications in patients receiving low-dose edoxaban | |
| Clinical research on factors affecting jaw osteonecrosis induced by drugs for bone metastasis | |
| Clinical investigation of factors affecting renal dysfunction caused by zoledronic acid | |
| Prediction of renal injury during multiple courses of cisplatin and search for influencing factors | |
| Examination of the usefulness of protocol-based test inputs by pharmacists in lung cancer patients treated with nivolumab and pembrolizumab | |
| Comparison of adverse events in sorafenib-regorafenib sequential therapy for hepatocellular carcinoma | |
| A clinical study on the incidence of febrile neutropenia (FN) and the factors affecting the incidence in docetaxel therapy for lung cancer | |
| Clinical survey on the incidence, timing and risk factors of skin disorders in bendamustine therapy for malignant lymphoma | |
| Issues in Tracing Report Operation at Kobe City Medical Center General Hospital and Examination of Countermeasures | |
| Clinical research on influencing factors related to efficacy and safety of immune checkpoint inhibitors | |
| Construction of a pharmacokinetic model for immune checkpoint inhibitors in patients with non-small cell lung cancer | |
| Study on conversion from hydromorphone injection to oral formulation | |
| Investigation on enhancement of the effect of warfarin by concomitant use of fentanyl | |
| Efforts of pharmacists as hepatitis medical coordinators at medical institutions specializing in liver diseases | |
| Antimicrobial Stewardship Team Intervention Effects Based on Process and Outcome Measures | |
| Association between the number of dose-adjusting factors and bleeding complications in patients receiving low-dose edoxaban | |
| Effect of short-term intravenous administration of amiodarone on warfarin anticoagulation after cardiac surgery | |
| Evaluation of efficacy and safety of cancer chemotherapy in diabetic patients | |
| Construction of treatment-related database of vancomycin-treated patients, extraction of influencing factors on pharmacokinetics and optimization of population parameters | |
| Investigation of side effects in administration of daptomycin and elucidation of factors affecting the occurrence of side effects | |
| Investigation of the relationship between changes in peripheral blood neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) after administration of immune checkpoint inhibitors (ICI) and immune-related adverse events (irAE) |
news
Fiscal year 2021 Announced in the magazine
book
- Toru Hashida (supervisor), Nobuyuki Muroi (eds.) Monthly special issue of pharmaceutical affairs. Strengthening book for first-year pharmacists. 2021.
- Nobuyuki Muroi. Types, composition, and characteristics of parenteral nutrition.JSPEN Textbook Japanese Society for Clinical Nutrition and Metabolism, 2021.
- Hiroaki Ikesue, Toru Hashida. Laxatives (laxatives). “New and different!
- Hiroaki Ikesue, Toru Hashida. The role of pharmacists. Handbook for the treatment of rare and intractable cancers.
- Nobuyuki Muroi, Toru Hashida. Development of pharmacists through the resident system. Pharma-Lead Next. 2: 2-5, 2022
- Okusada Satoshi. Kihon pharmacotherapy (1) (oral drugs, incretin-related drugs). Diabetes Care+. 19: 79-84, 2022
- Ikesue, Hiroaki. Preparation of pharmaceuticals based on prescriptions. (4) Chemical hazards.
paper
- Miura R, Hirabatake M, Irie K, Ikesue H, Muroi N, Kawakita M, Hashida T. Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer. Urol Oncol. 39: 233.e15-233.e20, 2021
- Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer. 29: 4763-4772, 2021
- Tanaka F, Shibatani N, Fujita K, Ikesue H, Yoshimizu S, Muroi N, Kurimoto Y and Hashida T. Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting. J Pharm Health Care Sci. 7: 17, 2021
- Yamashita K, Shimomura Y, Ikesue H, Muroi N, Yoshimoto A, Hashida T. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study. BMC Infect Dis. 21: 664, 2021
- Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Fukushimab S, Tomii K, Hashida T. Population pharmacokinetics of favipiravir in patients with COVID-19. CPT Pharmacometrics Syst Pharmacol. 10: 1161-1170, 2021
- Inoue M, Matsumoto K, Tanaka M, Yoshida Y, Satake R, Goto F, Shimada K, Mukai R, Hasegawa S, Suzuki T, Ikesue H, Liao J, Hashida T, Nakamura M. Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database. Sci Rep. 11: 11324, 2021
- Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol. 87: 871-877, 2021
- Satake R, Matsumoto K, Tanaka M, Mukai R, Shimada K, Yoshida Y, Inoue M, Hasegawa S, Iguchi K, Ikesue H, Shimizu S, Nishida S, Suzuki A, Hashida T, Nakamura M. Analysis of drug-induced gastrointestinal obstruction and perforation using the Japanese Adverse Drug Event Report Database. Front Pharmacol. 12: 692292, 2021
- Ogata M, Ama Y, Ogata T, Hirabatake M, Yasui H, Satake H. Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active cancer. In Vivo. 35: 2747-2753, 2021
- Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer. 30: 2341-2348, 2021
- Ikesue H, Yamamoto H, Hirabatake M, Hashida T, Chung H, Inokuma T, Muroi N. Risk factors of proteinuria in patients with hepatocellular carcinoma receiving lenvatinib. Biol Pharm Bull. 45: 333-338, 2022
- Ikesue H, Yamaoka K, Matsumoto A, Hirabatake M, Muroi N, Yamasaki T, Kawakita M, and Hashida T. Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. Cancer Chemother Pharmacol. Online ahead of print
- Eriko Kuramoto, Nobuyuki Muroi, Masaki Hirabatake, Haruna Hirayama, Naoki Shibatani, Asako Kii, Yasuo Kurimoto, Toru Hashida. Applicability of cefcapene pivoxil tablets as a postoperative prophylactic antibacterial agent in the clinical path of Ophthalmology day Japanese Society of Chemotherapy Journal. 69: 249-254, 2021
- Tomoya Tanaka, Yasuko Kurata, Naotake Takase, Mayuko Himoto, Toru Shinmen, Kazuki Dan, Makoto Kajizono, Yasuyuki Masaoka, Akihiko Nakamoto, Hideki Nawa, Yoshihisa Kitamura, Hiroaki Ikesue, Nobuyuki Muroi, Toshiaki Sendo, Miki Ikuko. A study of risk factors for proteinuria in patients treated with ramucirumab.
- Kunitaka Matsuishi, Haruko Fukushima, Kyohei Otani, Hiroyuki Miyai, Shigeru Tsuruya, Shuji Kawamura, Toshimichi Takahashi, Yoshiko Kuwata. Impact and countermeasures against the corona disaster in the clinical setting of the neuropsychiatric department of a general hospital with a new coronavirus infectious disease ward. Psychiatry Journal. 32: 829-836, 2021
- Hirohito Hama, Masaki Hirabatake, Hiroaki Ikesue, Nobuyuki Muroi, Toru Hashida. Consideration of expiration date setting for introduction of drug vial optimization. Cancer and Chemotherapy. 48: 1139-1143, 2021
- Kinoshita M., Ophthalmology N., Miyasaka M., Oe T., Hirano T., Irie K., Yoshimizu S., Fujiwara M., Kurimoto Y., Muroi N. Evaluation of ``glaucoma pharmacist outpatient services'' for glaucoma patients. 1113, 2021
review
- Muroi Nobuyuki. What is hospital practical training that leads to the development of clinical pharmacists? Pharmaceutical Education. 5: 2020-2024, 2021
- Nobuyuki Muroi. Community collaboration for patients with low vision: Low vision care linking hospitals to communities and the role of pharmacists. Pharmacy. 72: 2489-2493, 2021
- Ohe Y. Drug management seen by low vision patients. Pharmacy. 72: 2453-2457, 2021
- Tanaka I. Proposal of medicines requiring attention and alternative medicines for glaucoma. Pharmacy. 72: 2458-2464, 2021.
- Miyasaka M. Basic knowledge of eye drops. Pharmacy. 72: 2466-2472, 2021
- Naoki Shibatani. Development of ophthalmic device to support patients with low vision. Pharmacy. 72: 2473-2478, 2021
- Hirano T. Establishment and efforts of glaucoma pharmacist outpatient clinic. Pharmacy. 72: 2495-2505, 2021
- Yamada Kiyofumi, Hashida Toru. Direction of postgraduate pharmacist training. Journal of the Japanese Society of Hospital Pharmacists. 57: 1190-1196, 2021
- Ikesue H. Adverse drug monitoring and supportive care of anticancer drugs. Dispensing and information. 27: 1999-2004, 2021
- Ikesue H. Various situations in which cancer drug therapy becomes difficult to continue. Pharmacy. 72: 3326-3329, 2021
- Fujita T. Hand disinfection, article disinfection. Dispensing and information. 27: 2678-2683, 2021
- Tamura R. Home visit response to home care patients. Dispensing and information. 27: 2714-2718, 2021
- Muroi N, Yasuda Rie. Responding to mass vaccination of COVID-19 vaccines in communities. Dispensing and information. 27: 2719-2723, 2021
2020 Magazine announcement
book
- Ikesue H, Ito Y, Oishi R. Cancer chemotherapy worksheet 5th edition. Jiho, Tokyo, 2020
- Yukari Satsuma, Tatsuya Hirano: CQ6, CQ16: 2020 Guideline for Pharmacological Treatment of Cancer Pain, The Japanese Society for Palliative Medicine Guideline Management Committee (Editor), Kanehara Publishing, Tokyo, 2020
- Masatoshi Jinno, Hiroaki Ikesue (supervisor), Hiroyuki Watanabe (author). Evidence-based guidance for the development and management of cancer chemotherapy regimens. Yodosha, Tokyo, 2020
- Hiroaki Ikesue. Pharmaceutical Education Council Hospital and Pharmacy Practical Training Kinki District Coordination Organization (supervision). Hospital and pharmacy practical training textbook for pharmacy students 2021 edition. Prescription-based drug preparation. (4) Chemical Hazard. 94-96 , Jiho, Tokyo, 2021
- Hiroaki Ikesue. "Illnesses and medicines 2021" Anticancer drugs. 1480-1495, Nanzando, Tokyo, 2021
paper
- Takase T, Ikesue H, Nakagawa H, Kinoshita M, Muroi N, Kitai T, Furukawa Y, Hashida T. Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban. J Clin Pharm Ther. 45: 298–302, 2020
- Ikesue H, Kusuda K, Satsuma Y, Nishiwaki F, Miura R, Masuda Y, Hirabatake M, Muroi N, Fujimoto D, Morimoto T, Tomii K, Hashida T. Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. J Clin Pharm Ther. 45: 6, 1288-1294, 2020
- Torii H, Ando M, Tomita H, Kobaru T, Tanaka M, Fujimoto K, Shimizu R, Ikesue H, Okusada S, Hashida T, Kume N. Association of hypnotic drug use with fall incidents in hospitalized elderly patients: a case-crossover study. Biol Pharm Bull. 43: 925-931, 2020
- Ando M, Nishioka H, Nakasako S, Kuramoto E, Ikemura M, Kamei H, Sono Y, Sugioka N, Fukushima S, Hashida T. Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation. J Clin Pharm Ther. 45: 290-297, 2020
- Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Tomii K, Hashida T. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin Transl Sci. 13: 880-885, 2020
- Uchida M, Yamaguchi Y, Hosomi S, Ikesue H, Mori Y, Maegawa N, Takano A, Sato Y, Hosohata K, Muroi N, Tomii K, Hashida T, Nakamura T. Risk factors for febrile neutropenia induced by docetaxel chemotherapy in patients with non-small cell lung cancer. Biol Pharm Bull. 43: 1235-1240, 2020
- Uchida M, Mori Y, Akiba K, Miyasaka M, Hirano T, Ikesue H, Yamaguchi Y, Takano A, Maegawa N, Shimomura Y, Hosohata K, Muroi N, Ishikawa T, Hashida T, Nakamura T. Risk factors for skin toxicities associated with bendamustine-based chemotherapy in patients with non-Hodgkin lymphoma. Biol Pharm Bull. 43: 10, 1577-1582, 2020
- Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Inoue M, Satake R, Yoshida Y, Goto F, Hashida T, Nakamura M. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf. 29: 1279–1294, 2020
- Satsuma Y, Ikesue H, Kusuda K, Maeda M, Muroi N, Mori R, Kogo M, Hirabayashi R, Nagata K, Nakagawa A, Tachikawa R, Tomii K, Hashida T. Effectiveness of pharmacist-physician collaborative management for patients with idiopathic pulmonary fibrosis receiving pirfenidone. Front Pharmacol, 11:529654, 2020
- Matsumoto K, Hasegawa S, Nakao S, Shimada K, Mukai R, Tanaka M, Satake R, Yoshida Y, Goto F, Inoue M, Ikesue H, Iguchi K, Hashida T, Nakamura, M. Adverse event profile of Reye’s syndrome analyzed using the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. SAGE Open Medicine, 8: 1–9, 2020
- Yoshida S, Fujimoto A, Fukushima K, Ando M, Irie K, Hirano T, MiyasakaM, Shimomura Y, Ishikawa T, Ikesue H, Muroi N, Hashida T, Sugioka N. Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts. J Clin Pharm Ther. 46: 190-197, 2021
- Ohne M, Satsuma Y, Umeda S, Shinjo T, Nishimoto T, Ikesue H, Muroi N, Hashida T. Study on conversion from hydromorphone injection to oral formulation. Journal of The Japanese Society for Palliative Medicine. 15: 147- 151, 2020
- Nobori K, Doi M, Fujii N, Kii A, Muroi N, Hashida T. A case of HIV-infected very low birth weight infants treated with antiretroviral therapy (ART). Journal of the The Japanese Society for AIDS Research. 22: 106-110, 2020
- Makiko Doi, Hiroaki Nishioka, Madoka Ibaraki, Hiroaki Ikesue, Motozumi Ando, Naoki Higashibeppu, Nobuyuki Muroi, Toru Hashida. Appropriate total parenteral nutrition prescription by the nutritional support team -A study at our hospital-. JSPEN. 2 : 227-223, 2020
review
- Toru Hashida, Takashi Osawa, Koji Kashiwakura. Challenges and future prospects for medical economics with drugs. Pharmaceutical Sciences. 80: 229-232, 2020
- Muroi, Nobuyuki. Seamless collaboration in the transitional period such as hospital admission/discharge/perioperative period: drug therapy and pharmacist's role from hospital to community. Dispensing and information. 26: 1204-1211, 2020
- Muroi Nobuyuki. Pathophysiology and therapeutic agents for allergic rhinitis.
- Kazuko Tobiko, Nobuyuki Muroi. Column How should we consider the polypharmacy of cardiovascular drugs in an aging society. medicina. 58: 140-141, 2020
- Hiroaki Ikesue. Side effects of anticancer drug therapy series No. 4. Side effect management: immune-related adverse events (irAE). Japanese Journal of Clinical Oncology. 17: 11-19, 2020
- Ikesue Hiroaki. Efforts of education for understanding and disseminating evidence in clinical practice. Pharmaceutical Education. 4: 2020-035, 2020
- Muguruma R., Oku S., Tomita R., Masumoto N., Kuroda T., Tsujimoto T. Activity report in Hyogo Prefecture (Hyogo Prefecture Federation of Diabetes Educators). Medicine and Diabetes. 9: 201-206, 2020
2019 Magazine announcement
book
- Haruna Yamamoto: Anti-HCV drug. Drug interaction literacy for medical practice, Yoshiyuki Ohno, Akihiro Hisaka (editors), Nanzando, Tokyo, 184-188, 2019
- Daisuke Mioki: Guidance records for high-risk drugs. How to write a simple and easy-to-understand drug history and guidance record, Tadashi Terasawa (ed.), Nanzando, Tokyo, 90-101, 2019
- Hiroaki Ikesue: VEGF pathway inhibitor (angiogenesis inhibitor: polymer drug). Organizing and understanding anticancer drugs, Toshihiro Hama (supervisor), Jiho, Tokyo, 138-148, 2019
- Yoko Makihara, Hiroaki Ikesue: Lesson 8 Dealing with constipation. Learning from basic knowledge and cases: how to use drugs in palliative care for cancer, Yoshiaki Okamoto, Sachiko Arai (editors), Jiho, Tokyo, 112-119, 2019
- Ikesue H, Hashida T: Anti-cancer drugs. Therapeutic Drug Handbook 2020, Fumimaro Takahisa (supervisor), Jiho, Tokyo, 1008-1108, 2020
- Hiroaki Ikesue: Preparation of pharmaceuticals based on prescriptions. (4) Chemical hazards. Hospital and pharmacy practical training textbook for pharmacy students 2020 edition, Pharmaceutical Education Council.
paper
- Ando M, Nakasako S, Ariyoshi K, Yamaguchi M, Sakizono K, Minowa K, Fukushima S, Sugioka N, Hashida T: Re-elevation of serum amlodipine level after lipid emulsion therapy in an overdose case. J Clin Pharm Ther. 44: 970-973, 2019
- Takase T, Ikesue H, Nakagawa H, Kinoshita M, Muroi N, Kitai T, Furukawa Y, and Hashida T: Risk factors for major bleeding and clinically relevant non-major bleeding in Japanese patients treated with edoxaban. Biol Pharm Bull. 43: 458-462, 2020
- Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Uranishi H, Masuta M, Ikesue H, Hashida T, Iguchi K, Nakamura M: Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci. 17: 921-930, 2020
- Ando M, Hirabatake M, Yasui H, Fukushima S, Sugioka N, Hashida T. A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry. Biomed Chromatogr. 34: 3, e4776, 2020.
- Norio Masumoto, Yumiko Hisai, Kengo Hosomi, Yuki Sugita, Sachiko Komaki, Tomoko Inada, Hiroo Ohtsuki, Yusuke Nakagawa: A study on the usefulness of self-injection of liraglutide on admission in short-term hospitalized diabetic patients for coronary artery stent placement. Medications and Diabetes. 8: 299-306, 2019
review
- Nobuyuki Muroi: Evaluation of Diabetes Treatment and Management of Complications and Side Effects Evaluation of diet and exercise therapy in diabetes and its response. Pharmacy. 70: 1583-1587, 2019
- Nobuyuki Muroi: Basic knowledge of devices used in infusion and nutrition therapy. Pharmacy. 70: 1728-1732, 2019
- Haruna Yamamoto: A hospital pharmacist plays an active role as a hepatitis co. Hepatitis Medical Co Koredake - from the basics to examples of activities that make use of strengths that all occupations can be seen at a glance. Health, Labor and Welfare Research Grant "Study on verification and expansion of effectiveness of hepatitis measures from taking hepatitis virus test to receiving medical treatment" (Representative researcher: Yuichiro Eguchi) 2019 report
- Hiroaki Ikesue: Preoperative withdrawal of angiogenesis inhibitors. Monthly Yakuji special issue. 61: 2627-2628, 2019
- Hiroaki Ikesue: Measures against stomatitis caused by cancer treatment. Monthly Yakuji special issue. 61: 2629-2630, 2019
- Ikesue, H.: Methods of administration of G-CSF preparations. Monthly Yakuji special issue. 61: 2631-2632, 2019
- Kazuko Nobori: ACE inhibitor, ARB. HEART nursing. 32: 6-12, 2019
- Naoki Shibatani, Nobuyuki Muroi: Introduction to Kobe Eye Center Hospital Pharmacy Department and Efforts to Provide Medication Guidance to Low Vision Patients. Journal of the National Council of Municipal Hospitals. 58: 611-614, 2019
2018 Magazine announcement
book
- Muroi, Nobuyuki, Himoto, Mayuko, Takase, Naotake: Establishment of New Employee Education System by Introducing Tutor System - Making Use of Reflections from the Previous Year -. Theory and Practice of Hierarchical Human Resource Development in the Pharmaceutical Department, Tomohide Akase (ed.), Yakuzemi Farm Book, Saitama, 66-67, 2018
- Nobuyuki Muroi: Influence factors of adverse drug reactions. Environmental factors: nutritional status, diet, luxury goods, and polypharmacy. Assessment of Adverse Drug Reactions, Japanese Society of Drug Safety (supervisor), Nanzando, Tokyo, 40-43, 2019
- Nobuyuki Muroi: Influence factors of adverse drug reactions. Disability assessment. Scene 2 Shock caused by oxaliplatin (platinum drug) was suspected! . Assessment of Adverse Drug Reactions, Japanese Society of Drug Safety (supervisor), Nanzando, Tokyo, 86-89, 2019
- Nobuyuki Muroi: Influence factors of adverse drug reactions. General disability assessment. Scene 4 Suspected shock caused by infliximab (antibody drug)! . Assessment of Adverse Drug Reactions, Japanese Society of Drug Safety (supervisor), Nanzando, Tokyo, 95-98, 2019
- Nobuyuki Muroi: Influence factors of adverse drug reactions. Blood and hematopoietic disorder assessment. Scene 2 Granulocytopenia due to fluorouracil (anticancer drug) was suspected! . Assessment of Adverse Drug Reactions, Japanese Society of Drug Safety (supervisor), Nanzando, Tokyo, 153-156, 2019
- Hiroaki Ikesue: Preparation of pharmaceuticals based on prescriptions. (3) Chemical hazards. Hospital and Pharmacy Practical Training Textbook for Pharmaceutical Students 2019 Edition, Pharmaceutical Education Council, Hospital and Pharmacy Practical Training Kinki District Coordination Organization (supervisor), Jiho, Tokyo, 82-85, 2019
- Hiroaki Ikesue, Toru Hashida: Anticancer drugs. Therapeutic Drug Handbook 2019, Fumimaro Takahisa (supervisor), Jiho, Tokyo, 1008-1108, 2019
- Hirahata, M.: Venous thromboembolism. Clinical Oncology, Japanese Society of Clinical Oncology (ed.), Jiho, Tokyo, 657-663, 2019
- Ikesue, H.: Immune-related adverse events (irAEs). Clinical Oncology, Japanese Society of Clinical Oncology (ed.), Jiho, Tokyo, 769-776, 2019
paper
- Takase T, Ikesue H, Tohi M, Ueta H, Mima H, Koyama T, Hashida T: Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery. J Pharm Health Care Sci. 4: 13, 2018
- Yamamoto H, Ikesue H, Ikemura M, Miura R, Fujita K, Chung H, Suginoshita Y, Inokuma T, Hashida T: Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. J Pharm Health Care Sci. 4: 17, 2018
- Ikesue H, Nagano T, Hashida T: A case of acute kidney injury associated with dabrafenib and trametinib treatment for metastatic melanoma. Ann Pharmacother. 52：1051-1052, 2018
- Irie K, Shobu S, Hiratsuji S, Yamasaki Y, Nanjo S, Kokan C, Hata A, Kaji R, Masago K, Fujita S, Okada Y, Katakami N, Fukushima S: Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 1087-1088: 1-5, 2018
- Irie K, Okada A, Yamasaki Y, Kokan C, Hata A, Kaji R, Fukushima K, Sugioka N, Okada Y, Katakami N, Fukushima S: An LC-MS/MS method for absolute quantification of nivolumab in human plasma: application to clinical therapeutic drug monitoring. Ther Drug Monit. 40: 716-724, 2018.
- Okada A, Kariya M, Irie K, Okada Y, Hiramoto N, Hashimoto H, Kajioka R, Maruyama C, Kasai H, Hamori M, Nishimura A, Shibata N, Fukushima K, Sugioka N: Population pharmacokinetics of vancomycin in patients undergoing allogeneic hematopoietic stem-cell transplantation. J Clin Pharmacol. 58: 1140-1149, 2018
- Masago K, Irie K, Fujita S, Imamichi F, Okada Y, Katakami N, Fukushima S, Yatabe Y: Relationship between paronychia and drug concentrations of epidermal growth factor receptor tyrosine kinase inhibitors. Oncology. 95: 251-256, 2018
- Oshima E, Mibu M, Kubota M, Hashida T: Use of supplements by Japanese cancer patients receiving outpatient cancer chemotherapy. J Altern Complement Med. 24: 1003-1006, 2018
- Torii H, Shimizu R, Tanizaki Y, Omiya Y, Yamamoto M, Kamiike S, Yasuda D, Hiraoka Y, Hashida T, Kume N: Effects of ramelteon and other sleep-promoting drugs on serum low-density lipoprotein and non-high-density lipoprotein cholesterol: A retrospective comparative pilot study. Biol Pharm Bull. 41: 1778-1790, 2018
- Fujimoto K, Iwakura T, Aburaya M, Matsuoka N: Twice‑daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study. Diabetology & Metabolic Syndrome. 10: 64, 2018
- Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M, Yasui H, Hashida T, Kaihara S, Inokuma T, Tsuji A: Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection. Asia Pac J Clin Oncol. 15: 63-68, 2018
- Hirabayashi R, Fujimoto D, Satsuma Y, Hirabatake M, Tomii K: Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. Invest New Drugs 36: 952-954, 2018
- Maeda A, Irie K, Ando H, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Aoki M, Inaguma K, Kajita M, Fujimura A, Fukushima S: Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms. Cancer Chemother Pharmacol. 83: 107-113, 2019
- Irie K, Okada A, Masuda Y, Fukushima K, Sugioka N, Okuda C, Hata A, Kaji R, Okada Y, Katakami N, Fukushima S: Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy. J Oncol Pharm Pract. 25: 865-868, 2019
- Eriko Kuramoto, Masaki Hirabatake, Shinji Nakayoku, Motozumi Ando, Hiroaki Ikesue, Yuzo Hirai, Asako Yoshii, Toru Hashida: Efforts toward proper use of oral antibiotics after day surgery in the field of dentistry and their effects. Medical Pharmacy. 44: 422-428, 2018
- Yuki Takase, Hiroaki Ikesue, Misaki Kataoka, Masaki Oyama, Daisuke Mioki, Naoko Fujii, Sadachi Oku, Nobuyuki Muroi, Toru Hashida: Introduction and effects of an in-hospital protocol in which pharmacists answer questions about out-of-hospital prescriptions. Medical Pharmacy. 45: 82-87, 2019
- Yuki Nakagawa, Ikuko Miki, Naotake Takase, Tomoya Tanaka, Ayaka Miura, Tsuneo Hamaguchi, Yujiro Takao, Makoto Katsuya, Yasuhiro Mitsui, Nobuyuki Muroi: Side effects of direct-acting antivirals (DAAs). Consideration of the situation and risk factors. Journal of Japanese Medicine. 55: 177-182, 2019
review
- Toru Hashida: The first step is essential for training talented pharmacists who are active in the medical field. Pharmaceutical Education. 2: 113-116, 2018
- Hiroaki Ikesue: Drug therapy management from hospitalization to perioperative period and post-discharge. 29: 4-8, 2019
- Ikesue, H.: Adjuvant drugs for cancer treatment. Pharmaceutical journal special issue. New drug prospects 2019.
2017 Magazine announcement
book
- Toru Hashida, Hiroaki Nishioka (editors)
- Pharmacist Resident Manual 2nd Edition. Igaku Shoin, Tokyo, 2018
- Hiroaki Ikesue (partial author). Chitetsu Yoshimura, Kazuo Tamura (supervision) Edema. Cancer Drug Therapy Side Effects Management Manual, Igakushoin, Tokyo, 103-9, 2018
- Hiroaki Ikesue, Masaki Hirahata (partial author). Japanese Society of Pharmaceutical Health Care and Sciences (editor) Prostate cancer. Understanding and assembling pathological conditions. Disease-specific drug therapy for pharmacists I. Malignant tumor, Nankodo, Tokyo, 46-59, 2018
- Hiroaki Ikesue (partial author) Anti-cancer drug. Pharmacy special issue. Illness and Medicine 2018, 69: 1438-1452, Nanzando, Tokyo, 2018
- Hiroaki Ikesue (contributor). Yuichi Ando, Chisuke Terada (editing). Hironobu Minami (supervisor) Cancer drug therapy in a special clinical background: a case of poor PS. Cancer drug therapy handbook for high-risk patients, Yodosha, Tokyo, 296-301, 2017
paper
- Ikemura M, Hashida T: Effect of hyperglycemia on antitumor activity and survival in tumor-bearing mice receiving oxaliplatin and fluorouracil. Anticancer Res 37: 5463-8, 2017
- Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D, Irie K, Okada H, Fukushima S, Katakami N: Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer 118: 32-7, 2018
- Uchida M, Nakamura T, Makihara Y, Suetsugu K, Ikesue H, Mori Y, Kato K, Shiratsuchi M, Hosohata K, Miyamoto T, Akashi K: Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy. Pharmazie 73: 304-8, 2018
- Kusuda, K., Nishioka, K., Ikemura, M., Higashibeppu, N., Nishioka, A., Hashida, T.: Effect of gastric acid secretion inhibitors on diarrhea-improving effect of concentrated liquid diet containing pectin. Japanese Journal of Parenteral and Enteral Nutrition 32: 988-91, 2017
- Mai Ikemura, Motozumi Ando, Toru Hashida: Proposal of a support method for clinical research by pharmacists. Pharmaceutical Education 1: 2017
- Hatanaka Y, Miura R, Nagata K, Oku Sada, Ikesue H, Fujimoto D, Iwamoto Y, Nakagawa J, Ueno S, Mitsuishi T, Okushin H, Tomii K, Hashida T: Interaction between febuxostat and azathioprine A case of pancytopenia induced by action. Japanese Journal of Hospital Pharmacists 54: 53-6, 2018
- Nobuko Takayanagi, Masahiro Okuno, Yoshiyasu Kubo, Akiko Hashimoto, Yasuhiro Tanaka, Toshio Takafuta, Isaki Niisato, Hiroaki Ikesue, Manabu Nakata: Influence of prescription suggestions from pharmacists attending doctor 's examinations on lenalidomide treatment. Japanese Journal of Hospital Pharmacists 54: 167-74, 2018
review
- Oku, S.: Answering patients' questions about medicines Medicine Q&A (1) Insulin injection. Monthly Diabetes Life Sakae 58: 23, 2018
- Shigefumi Morimoto: Great expectations for this season's Chemo League. Professional Cancer Nursing 7: 14-5, 2017
- Shigefumi Morimoto: Big expectations for this season's Kemo League. The director talks about cancer-specific team strategies! Cancer Chemotherapy Drug Player Directory. Professional Cancer Nursing 7: 45-7, 2017
2016 Magazine announcement
book
- Tsuyoshi Aoyama, Kanako Higashi, Hiroaki Ikesue, Kazuyoshi Kawakami, Junya Sato, Hironobu Hashimoto (Editor). Toshihiro Hama (Supervisor)
Cancer chemotherapy regimen management manual 2nd edition. Igaku Shoin, Tokyo, 2016 - Hiroaki Ikesue (partial author), Yutaka Furukawa (editor)
Basics and therapeutic agents for malignant neoplasms. Anticancer drugs. - Illness and Medicine 2016, Pharmacy Special Edition, Nanzando, Tokyo, 1342-55, 2016
paper
- Rumiko Shimizu, Haruki Torii, Daisuke Yasuda, Yoshinori Hiraoka, Yutaka Furukawa, Akihiro Yoshimoto, Toshio Iwakura, Naoki Matsuoka, Keisuke Tomii, Nobuo Kohara, Tohru Hashida, Noriaki Kume: Comparison of serum lipid management between elderly and non-elderly patients with and without coronary heart disease (CHD). Prev Med Rep 4: 192-8, 2016
- Kimitaka Suetsugu, Hiroaki Ikesue, Toshihiro Miyamoto, Motoaki Shiratsuchi, Nanae Yamamoto-Taguchi, Yuichi Tsuchiya, Kumi Matsukawa, Mayako Uchida, Hiroyuki Watanabe, Koichi Akashi, Satohiro Masuda: Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Int J Hematol 105: 361-8, 2017
- Kaori Kanemitsu, Shigefumi Morimoto, Noriaki Kitada, Wasaburo Kataoka, Takuya Aoki, Shinya Yoshioka, Masato Kita, Toru Hashida: A study on the necessity of recommending rubella vaccination based on rubella antibody titers in pregnant women. Iryo pharmacy 42: 687-93, 2016
- Sugiyama Y, Ikemura M, Oku Sadatomo, Iwakura T, Hashida T: Evaluation of glycemic control by switching from existing long-acting insulin to insulin degludec in patients with type 1 diabetes mellitus. Iryo pharmacy 42: 562-8, 2016
- Ishida S, Takeda M, Ogawa R, Nakajima T, Ikesue H, Watanabe H, Kanaya A, Egashira N, Masuda T: Development of a quick reference table for injection formulation changes in intensive care units and evaluation of its usefulness. 286-94, 2016
- Narumi Kanokogi, Ohtaku Suetsugu, Atsushi Takada, Hiroaki Ikesue, Hiroyuki Watanabe, Mion Fukuda, Yuriko Ryokai, Akiko Kanaya, Nobuaki Egashira, Satosaki Masuda: Improving the efficiency of drug information management guidance at the time of discharge by constructing an IT support system. Japanese Journal of Hospital Pharmacists 52: 882-6, 2016
review
- Ikesue H, Hata K, Ryokai Y, Ohata S, Suetsugu O, Watanabe H, Masuda T: Occurrence timing and risk factors for hypocalcaemia associated with denosumab, a therapeutic agent for cancer bone metastasis. Advances in Clinical Pharmacology 142-8 , 2016
2015 Magazine announcement
book
- Toru Hashida, Hiroaki Nishioka (editors). Cardinal Rule of Pharmacist Resident, Igaku Shoin, Tokyo, 2016
paper
- Mai Ikemura, Shinji Nakasako, Ryutaro Seo, Takahiro Atsumi, Koichi Ariyoshi, Tohru Hashida: Reduction in gastrointestinal bleeding by development and implementation of a protocol for stress ulcer prophylaxis:a before-after study. J Pharm Health Care Sci 1: 33, 2015
- Rumiko Shimizu, Haruki Torii, Daisuke Yasuda, Yoshinori Hiraoka, Noriaki Kitada, Tohru Hashida, Akihiro Yoshimoto, Toru Kita, Noriaki Kume: Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines. A Single-Center Study. J Pharm Health Care Sci 22: 949-57, 2015
- Hirohito Hama, Shoji Tanaka, Toru Hashida: Decontamination effect of anticancer drug-contaminated environment using ozonated water and sodium hypochlorite. Japanese Journal of Medical Pharmaceutical Sciences 41: 740-49, 2015
- Mai Ikemura, Toru Hashida: Evaluation of research experience based on a postgraduate course aimed at fostering Pharmacist-Scientists. YAKUGAKU ZASSHI 135: 131-7, 2016
review
- Mieko Ooto Delirium Special Part-1 Why? Why Delirium Care Is Important. Nurse Senka 1: 16-9, 2016
- Ooto, Mieko Special issue on delirium PART-3 Let's identify delirium from risk factors. Nurse Senka 1: 33-4, 2016
2015 academic conference presentations and lectures
- Hashida T：Special Lecture II The New Role Required for Pharmacists in Cancer Pharmacotherapy. The 13th China-Japan-Korea (CJK) Joint Symposium for Clinical Information on Parenteral Drugs in Kyoto，2015.4.18
- Motozumi Ando, Eriko Kobiki, Shinji Nakasako, Hiroko Kashiwagi, Noriaki Kitada, Shigefumi Morimoto, Hiroki Kamei, Yumi Sono, Hiroaki Nishioka, Tsuyoshi Fukuda, Tohru Hashida: Safety and pharmacokinetics of daptomycin in Japanese patients, IATDMCT 2015, Rotterdam,2015.10.11-15
- Toru Hashida: Outpatient Pharmacist for Cancer Patients -Including Tips for Calculating Guidance and Management Fees for Cancer Patients-, Nagoya Clinical Pharma Symposium, Nagoya, 2015.21
- Yuriko Sugiyama, Mai Ikemura, Satoru Okusada, Toshio Iwakura, Toru Hashida: Study on switching from twice daily administration of existing sustained-release insulin to once daily administration of degludec in type 1 diabetic patients. The 58th The Japan Diabetes Society Annual Scientific Meeting, Shimonoseki, 2015.5.21-24
- Chiyo Yamamoto: Aiming to improve drug adherence in Hyogo Prefecture treatment - the current situation of outpatient pharmacists at our hospital -.
- Toru Hashida: Expectations for pharmacists who will be responsible for future medical care, 2015 National Saiseikai Hospital Pharmacist Association Workshop, Osaka, 2015.5.30
- Toru Hashida: The Role of Cancer Pharmacists in Cancer Drug Treatment, Osaka University of Pharmaceutical Sciences 8th Public Symposium, Takatsuki, 2015.6.5
- Toshihiko Inazumi: The role of pharmacists in the palliative care team of acute care hospitals.
- Toru Hashida: Career path of a pharmacist starting from a pharmacist resident, Annual meeting of the Japanese Society of Health Management, Osaka, 2015.6.13
- Haruna Yamamoto: Side effects of two-drug oral treatment with daclatasvir and asunaprevir for hepatitis C. The 30th Higashi-Kobe Gastrointestinal Disease Seminar, Kobe, June 18, 2015.
- Toru Hashida: Aiming to become a pharmacist active at the forefront of medical care, Meijo University Faculty of Pharmacy Dream and Discovery Seminar, Nagoya, 2015.6.20
- Satoshi Okusada: A pharmacist connects seamless drug treatment from pre-hospitalization to discharge. Workshop of the National Association of Pharmacy Managers of City Hospitals, Kobe, July 3, 2015.
- Toru Hashida: Total management of anticancer drugs - zero exposure and rewarding workplace -, The 1st Meeting of the Japanese Society of Drug Safety, Fukuyama, 2015.7.4-5
- Moena Miyasaka, Mieko Oone, Shigefumi Morimoto, Satoko Ito, Noboru Kitamura, Toru Hashida: Intervention by pharmacists for patients using yokukansan in the delirium team. Medical Pharmacy Forum, Nagoya, 2015.7.4-5
- Naoki Shibatani, Eriko Kobiki, Satoshi Okusada, Shigefumi Morimoto, Toru Hashida: Introduction of practical training program using the roof tile method for training pharmacists with practical ability. Medical Pharmacy Forum, Nagoya, 2015.7.4-5
- Toru Hashida: Mechanism and People Supporting Safety of Drug Treatment, The 40th Kagawa Prefectural Clinical Pharmacist Workshop, Takamatsu, 2015.7.21
- Toru Hashida: A new pharmacy business that realizes seamless drug treatment - outpatient pharmacist and regional cooperation -, 2015 Hiroshima pharmacist workshop, Hiroshima, 2015.7.26
- Shigefumi Morimoto: Clinical questions from the point of view of work -The road to clinical research and establishment of a data center-. Hanshin Area Pharmacy Seminar, Nishinomiya, 2015.7.29
- Kaori Yamamoto: The role of a pharmacist who supports outpatient treatment-all for cancer patients! ~. The 25th Annual Meeting of the Kansai Injection Practical Forum, Osaka, August 8, 2015
- Satoshi Okusada: Pharmaceutical management and pharmacist work.Introduction to Kobe City College of Nursing Training Department of Pharmacy, Kobe, September 9, 2015
- Okusada, S., Tomita, R., Nishihama, T., Masumoto, N., Muguruma, R., Tsujimoto, T.: Verification of the activities of the Hyogo Prefecture Federation of Diabetes Educators: Training and educational effects based on the results of a questionnaire survey. The 4th Annual Meeting of the Japanese Society of Medicine and Diabetes Annual meeting, Niigata, September 26-27, 2015
- Nakayaku Shinji: Factors affecting the efficacy of antimicrobial agents, drug interactions, and TDM. Japanese Nursing Association, 2015 Infection Control Certified Nurse Education Course, Kobe, 2015.9.29.
- Mieko Ohne, Yukari Satsuma, Toshihiko Inazumi, Setsuko Umeda, Mio Li, Toru Hashida: Efforts of our hospital toward the safe use of fentanyl citrate sublingual tablets and their usefulness. The Pharmaceutical Society of Japan, Yokohama, 2015.10.2-4
- Misao Sakuma, Satoshi Okusada, Kiyomi Shigehira, Miyako Mizumoto, Yoshiko Tomizawa, Kenji Uriuhara: Drug risk avoidance by interdisciplinary collaboration in pre-hospital examination center: Early intervention and its evaluation by collaboration of nurses and pharmacists in the perioperative period ~. The 54th Annual Meeting of the Japanese Association of Municipal Hospitals, Hakodate, 2015.10.8-9
- Satoshi Okusada: Types and usage of diabetes drugs (oral) - Patient guidance methods - Diabetes Seminar, Hyogo Prefecture Association of Diabetes Educators, Kobe, October 11-12, 2015
- Satoshi Okusada: Rethinking the relationship with diabetes patients. DM FLAG in Hyogo, Kobe, 2015.10.15
- Kazuko Nobori: Considering secondary prevention of cardiovascular disease -from the perspective of a pharmacist-.
- Shinji The Japanese Association for Infectious Diseases: Pharmacokinetics of antibiotics that should be noted in clinical practice (educational lecture).
- Masaki Hirahata: Aiming to maximize therapeutic effects through appropriate side-effect management -Efforts at each facility-.
- Toru Hashida: Pharmacy Department Management in Acute Hospitals - Strategies and Functions for Dealing with Rapidly Changing Medical Environment -, 1st Kumamoto City Public Hospital Pharmacy Director Management Conference, Kumamoto, 2015.10.27
- Toru Hashida: Symposium, The practice of cancer drug therapy to support employment, The 53rd Annual Meeting of the Japan Society of Clinical Oncology of Oncology, Kyoto, 2015.10.29-31
- Mieko Ooto: Ideas to prevent incidents due to delirium care ~Role of pharmacists in the delirium team~ Hyogo Prefecture Nursing Association Branch Joint Workshop (Kobe Chubu), Kobe, 2015.11.14
- Ikemura M, Nakayoku S, Fujiwara H, Fujiwara M, Doi M, Seo R, Atsumi I, Ariyoshi K, Hashida T: Improvement of stress ulcer prophylaxis by protocol-based pharmacotherapy management. Meeting, Yokohama, 2015.11.21
- Takase Y, Doi M, Fujiwara H, Tobiko K, Morimoto S, Hayasaka T, Ueda K, Ikemura M, Hashida T: PT-INR can be controlled by combination of warfarin, bucolome and amiodarone in response to metabolic enzyme induction by rifampicin 1 case.
- Haruna Yamamoto, Kaori Yamamoto, Ayako Sakon, Mai Ikemura, Hiroshi Tei, Yoshiki Suginoshita, Tetsuro Inokuma, Toru Hashida: Establishment and Evaluation of Outpatient Pharmacists for Hepatitis C Interferon-free Patients, Vol. 25th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Yokohama, 2015.11.22
- Toru Hashida: Pharmacy services from pre-hospitalization to perioperative period, transfer and discharge, The 25th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Yokohama, 2015.11.21-23
- Toru Hashida: Utilization of outpatient pharmacist aiming to improve anticancer drug adherence, The 25th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Yokohama, 2015.11.21-23
- Toru Hashida: Seamlessly connecting pharmacotherapy from inpatient/outpatient to community, The 8th Academic Lecture Meeting of Kyoto Pharmaceutical Association Maizuru District, Maizuru, 2015.11.25
- Mieko Ohne: The role of pharmacists in the delirium team. Osaka Pharmaceutical Association Delirium Lecture, Osaka 2015.11.27
- Haruna Yamamoto: Efforts of hospital pharmacists for hepatitis C interferon-free treatment and cooperation with demand pharmacies.Hyogo Hospital Pharmacists Association Hepatitis C Pharmacist Seminar 2015, Hyogo Prefecture, 2015.11.27
- Satoshi Okusada: Rethinking the relationship with diabetes patients. The 2nd Awaji Pharmacist Team Conference, Awaji, Hyogo Prefecture, December 3, 2015.
- Masaki Hirabatake: CDTM in Cancer Chemotherapy. 6th University-Medical Collaboration Lecture (Kobe Gakuin University), Kobe, 2015.12.4
- Toru Hashida: Responding to growing needs of ward pharmacists, Shinshu ward pharmacist seminar, Matsumoto, 2015.12.11
- Shimizu, Risa, Shibatani, Naoki, Ikemura, Mai, Okusada, Satoshi, Morimoto, Shigefumi, Hashida, Toru: Practical training programs prior to the new model core curriculum for pharmacy education and their issues. .23-24
- Misao Sakuma, Yukako Yoshino, Satoshi Okusada, Mai Ikemura, Kiyomi Shigehira, Miyako Mizumoto, Yoshiko Tomizawa, Shigefumi Morimoto, Kenji Uryuhara, Toru Hashida: doctor and nurses for pharmacist early intervention for regular drugs before hospitalization・Evaluation of pharmacists.
2014 Magazine announcement
book
- Kaori Kanemitsu (partial writing), Yutaka Furukawa (editing)
Specifics II 48 key points for smooth ward work 1. Bringing medication management 1-3. Perioperative period. Ward Pharmacy Handbook, Jiho, Tokyo, 59-61, 2014 - Noriaki Kitada (partial writing), Yutaka Furukawa (editing)
Detailed discussion II 48 key points for smooth ward operations 5. Protocol creation. Ward Pharmacy Handbook, Jiho, Tokyo, 86-7, 2014 - Shigefumi Morimoto (partial author), Yutaka Furukawa (editor)
Detailed discussion II 48 key points for smooth ward work 6. Side effect monitoring 6-2.Evaluation and recording by CTCAE. Ward Pharmacy Handbook, Jiho, Tokyo, 94-5, 2014 - Shinji Nakayu (partial writing), Yutaka Furukawa (editing)
Detailed discussion II 48 key points for smooth ward operations 7. Coordination with other occupations 7-2. Rapid information sharing and teamwork formation. Ward Pharmacy Handbook, Jiho, Tokyo, 100-4, 2014
paper
- Morimoto, S., Miyabe, T., Inoue, A., Hata, H., Tanijima, H., Maeda, T., Shono, Y., Nakatani, F., Fujita, Y., Yamazaki, K., Horiuchi, T.: Early hematotoxicity and nutritional assessment index PNI due to mFOLFOX6 therapy. Surgery and Metabolism/Nutrition 48: 59-67, 2014
- Haruna Yamamoto, Noriaki Kitada, Naoki Shibatani, Masaki Hirabatake, Toru Hashida: Points to note for risk minimization activities at the time of introduction of new drugs and the role of pharmacists. Pharmaceutical informatics 16: 28-32, 2014
- Tanaka T, Takeuchi M, Hashida T, Kotake K, Uchikawa S, Imaizumi Y: Effects of promotion of ward pharmacy work on drug management instruction work and drug-related incidents. Journal of the Japanese Society of Hospital Pharmacists 50: 1226-9, 2014
Review, etc.
- Miyuki Sakurai, Setsuko Anan, Hiromasa Ishimaru, Chiga Fujii, Shigefumi Morimoto, Sumiyo Iwamoto, Hitoshi Yoshida: Fiscal 2013 Scientific Committee 7th Scientific Subcommittee Report Investigation and research toward the creation of guidelines for the safe handling of anticancer drugs (final presentation). Japanese Journal of Hospital Pharmacists 50: 1065-71, 2014
- Toru Hashida: Pharmacist Resident System Current Situation in Japan and Efforts at Our Hospital. Journal of the National Municipal Hospital Council 53: 881-6, 2014
- Mai Ikemura, Toru Hashida: [Dosage forms and proper use of therapeutic drugs for neurological disorders] Pharmaceutical characteristics of tablets and extended-release tablets. Brain Medical 26: 95-102, 2014
- Toru Hashida: Pharmacy management with a view to hospital missions. Pharmacy 65: 2574-80, 2014
- Toru Hashida: [Medical safety that surgeons should know] Active involvement of pharmacists in medical safety. Gastroenterological Surgery 37: 1703-10, 2014
- Toru Hashida: [Role of hospital pharmacists in team medical care] Roles of hospital pharmacists in outpatient team medical care and human resource development. Hospital 73: 779-83, 2014
- Toru Hashida: [Practical hints for pharmacist education - Developing pharmacist skills!] Education for new and young employees learned from the resident program The resident system in Japan and the case of Kobe City Medical Center General Hospital. Monthly Pharmaceutical Affairs 56: 1969-75, 2014
- Oku, S., Hashida, Toru: Pharmaceutical intervention for perioperative patients (aiming for seamless involvement): points of pharmacological management: preoperative (outpatient/prehospital). Monthly Pharmaceutical Affairs 57: 27-33, 2015
2014 academic conference presentations and lectures
- Tamaki, R., Mori, A., Yanagihara, G., Amano, F.: Biology and Pathology of Chemotherapeutic treatment for Gastric scirrhous cancer. Drug Discovery & Therapy World Congress 2014, Boston (USA), 2014.06.18
- Chiyo Yamamoto, Kei Irie, Yu Okada, Yuichiro Ono, Naoko Hashimoto, Takayuki Ishikawa, Toru Hashida: Effect of Neurokinin-1 Receptor Antagonist on Tacrolimus Concentration in Allogeneic Stem Cell Transplantation. The 3rd International Symposium of Training Plan for Oncology Professionals, Osaka, 2015.02.07
- Toshihiko Inazumi: A case of cancer of unknown primary that was difficult to spend in the supine position due to low back pain. The 15th Hanshin Palliative Pharmacotherapy Network, Amagasaki, 2014.04.08
- Sadatomo Oku: Consciousness and efforts of medical staff regarding sugar-restricted diets: pharmacist's response based on questionnaire survey results. Lecture at the 13th Hyogo Prefecture Association of Diabetes Educators, Kobe, 2014.04.19
- Shigefumi Morimoto: What I learned from calculating cancer patient guidance and management fees I. 3rd Active Pharmacist Seminar in HYOGO, Kobe, 2014.05.16
- Masaki Hirabatake, Toru Hashida: Report on current status and issues of antiemetic therapy for moderately emetogenic anticancer drugs. 6th JSOPP, Tokyo, 2014.05.18
- Morimoto, S., Hata, Y., Miyabe, T., Yamazaki, K.: Report on the current status and issues of exposure control. The 6th Annual Meeting of the Japanese Society of Pharmacognosy of Cancer (JSOPP), Tokyo, 2014.05.18
- Masaki Hirahata: Drug treatment management and prescription proposal based on agreement between doctor and pharmacists. 2014 National, Public and Private University Hospital Medical Technology Staff Training, Tokyo, 2014.05.29
- Masaki Hirahata: Cancer medicine and pharmacology. Cancer Nursing Training, Kobe, 2014.05.29
- Toru Hashida: Active involvement of pharmacists in medical safety. 1st Multiprofessional Interdisciplinary Symposium of Japan Society for Medical Safety, Osaka ，2014.05.31
- Toru Hashida: Missions and Challenges of a New Era Pharmacist. Chiba Prefecture Hospital Pharmacist Summit, Chiba, 2014.6.14
- Shigefumi Morimoto: My Encounter with Clinical Research and Why I Want to Continue. The 3rd University-Medical Collaboration Lecture, Kobe, 2014.07.04
- Toru Hashida: Construction and current situation of pharmacist outpatient clinics. Ehime Prefectural Hospital Pharmacist Association Lecture, Matsuyama, 2014.7.5
- Shinji Nakayoku: To become a disaster-resistant pharmacist -Learn from experience and prepare for the next time-. Lecture hosted by Hyogo Prefecture Pharmacist Association Training Department, Kobe, 2014.07.13
- Shinji Nakayoku, Motozumi Ando, Makoto Sono, Yoko Asaka, Akira Inoue, Ryutaro Seo, Ikuhiro Atsumi, Koichi Ariyoshi, Noriaki Kitada, Shigefumi Morimoto, Toru Hashida: Chronological Study of Drug Concentrations in Patients Taking Overdose Amlodipine 1 case measured at . The 36th Annual Meeting of the Japanese Society for Clinical Toxicology, Tokyo, 2014.07.25
- Morimoto, Shigefumi: Side effect management. Lung Cancer Team Medical Care Promotion Forum (Japan Lung Cancer Society), Osaka, 2014.07.27
- Tanihara, A., Fujiwara, A., Okusada, Kanako, Oku, S., Nishida, A., Kitada, N., Kadomoto, M., Koike, M., Hashida, T. Survey on ophthalmic drug compliance guidance by pharmacists and preparation of explanatory documents for ophthalmic drugs for patients. evaluation. The 5th Annual Meeting of the Japanese Society of Applied Therapeutics, Kobe, 2014.08.02
- Rie Tamaki: Current status and problems in clinical trials from the perspective of CRC. Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) Summer Seminar Thinking about clinical trials in gastrointestinal cancer, Osaka, 2014.08.09
- Yuko Yagi, Masaki Hirabatake, Hiromichi Nomura, Shinya Nakanishi, Noriaki Kitada, Akihito Tsuji, Takayuki Ishikawa, Keisuke Tomii, Toru Hashida: Efforts and evaluation of pharmacy department for hepatitis B caused by immunosuppression and chemotherapy. The 52nd Annual Meeting of the Japan Society of Clinical Oncology of Oncology, Yokohama, 2014.08.30
- Kaori Yamamoto: Fact-finding survey on changes in blood coagulability in patients concomitant with S-1 and warfarin. The 52nd Annual Meeting of the Japan Society of Clinical Oncology of Oncology, Yokohama, 2014.08.30
- Shiho Sato, Shiori Yumiki, Naoki Shibatani, Shuichi Kishimoto, Noriaki Kitada, Kazuko Nishioka, Takuya Aoki, Nobuo Inotsume, Toru Hashida, Shoji Fukushima: Blood concentration of ritodrine for the treatment of threatened premature birth and genetic polymorphisms of SULT1A1 and β2 adrenergic receptors . The 64th Kinki Branch General Meeting of the Pharmaceutical Society of Japan, Kyoto, 2014.09.13
- Rie Tamaki, Shigefumi Morimoto, Akihito Tsuji: Cancer clinical trials and diversification of CRC work. The 15th Kansai Cancer Team Medical Study Group, Osaka, 2014.09.13
- Masaki Hirabatake, Hiroki Ito, Yuko Yagi, Hiromichi Nomura, Shinya Nakanishi, Akiko Matsushita, Toru Hashida: Measures against hepatitis B caused by immunosuppression and chemotherapy in post-cancer chemotherapy patients. The 1st Annual Meeting of the Japan Society for Medical Safety, Tokyo, 2014.09.21
- Sadatomo Oku: Usefulness of regular drug confirmation by pharmacist outpatient before hospitalization. The 1st Annual Meeting of the Japan Society for Medical Safety, Tokyo, 2014.09.22
- Sadatomo Oku: Linking pharmaceutical management from pre-hospitalization to discharge adjustment. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
- Kaori Kanemitsu, Noriaki Kitada, Shigefumi Morimoto, Takuya Aoki, Masato Kita, Wasaburo Kataoka, Toru Hashida: Study on rubella vaccination in pregnant women based on rubella antibody titer. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
- Yuko Yagi, Masaki Hirabatake, Hiroki Ito, Hiromichi Nomura, Shinya Nakanishi, Akiko Matsushita, Toru Hashida: Measures against hepatitis B caused by immunosuppression and chemotherapy in patients after hematopoietic stem cell transplantation. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
- Masaki Hirabatake, Shigefumi Morimoto, Haruna Yamamoto, Noriaki Kitada, Toru Hashida: Requirement development and issues for cancer patient guidance and management work based on pharmacist outpatient experience. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
- Kazuko Nobori, Toru Hashida: Pharmacists specializing in drug therapy and how to compile case summaries (cardiovascular disease). The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
- Motozumi Ando, Eriko Kobiki, Shinji Nakayoku, Yuko Kashiwagi, Noriaki Kitada, Hiroki Kamei, Satomi Sono, Hiroaki Nishioka, Tsuyoshi Fukuda, Toru Hashida: Safety of the anti-MRSA drug daptomycin and usefulness of blood concentration monitoring. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.28
- Nakayasu, Shinji: Factors affecting the efficacy of antimicrobial agents, drug interactions, and TDM. Nursing Association 2014 Infection Control Certified Nurse Education Course, Kobe, 2014.09.30
- Inazumi, T., Satsuma, Y., Sakon, A., Kongo, K., Ohne, M., Kitada, N., Umeda, S., Lee, M., Hashida, T.: Intervention and evaluation by pharmacists in the palliative care outpatient clinic, 2nd report. The 8th Annual Meeting of the Japanese Society of Palliative Medicine, Matsuyama, 2014.10.04
- A. Sakon, Y. Satsuma, M. Oon, T. Inazumi, N. Kitada, S. Umeda, Mio Li, T. Hashida: Evaluation of adjuvant analgesic effect and safety of duloxetine hydrochloride in cancer patients. The 8th Annual Meeting of the Japanese Society of Palliative Medicine, Matsuyama, 2014.10.04
- Sadatomo Oku: Diabetes seminar lecture Diabetes drug (oral). Diabetes Educator Hyogo Prefecture Association "Diabetes Seminar", Kobe, 2014.10.12
- Shigefumi Morimoto: What I learned from calculating cancer patient guidance and management fees II. 10th Kansai Psycho-Oncology Study Group, Osaka, 2014.10.31
- Toru Hashida: A paradigm shift in pharmacy work with expertise, The 56th Public Symposium of the Japanese Society of Pharmaceutical Health Care and Sciences, Sapporo, 2014.11.01
- Oku, S., Tomita, R., Nishihama, T., Masumoto, N., Muguruma, R., Tsujimoto, T.: Awareness survey on the early introduction of insulin injections. The 3rd Annual Meeting of the Japanese Society of Medicine and Diabetes, Fukuoka, 2014.11.02
- Sugiyama Y, Ikemura M, Oku Sadatomo, Kitada N, Iwakura T, Hashida T: Efficacy and safety of insulin degludec in patients with type 1 diabetes. The 3rd Annual Meeting of the Japanese Society of Medicine and Diabetes, Fukuoka, 2014.11.02
- Toru Hashida: Management of pharmacy business shifting to outpatient. Osaka Municipal Hospital Pharmacy Director Academic Lecture, Osaka, 2014.11.7
- Toru Hashida: Outpatient pharmacist for cancer patients. Kansai Clinical Pharma Symposium, Osaka, 2014.11.08
- Shigefumi Morimoto: Practical guidance and management of cancer patients based on pharmacological knowledge. Hyogo Oncology Pharmacy Seminar, Kobe, 2014.11.12
- Nakayaku, S.: The role of pharmacists in disaster medicine. The 62nd Annual Meeting of the Japanese Society for Occupational Accident Medicine, Kobe, 2014.11.16
- Shigefumi Morimoto: The practical approach to cancer patients, such as guidance and side effects, and the role of pharmacists, making the most of hospital ward work. Osaka Prefectural Hospital Pharmacists Association 2014 2nd Ward Pharmacy Workshop, Osaka, 2014.11.18
- Toru Hashida: Total management of anticancer drugs. Wakayama Oncology Pharmacy Seminar, Wakayama, 2014.11.22
- Rie Tamaki: Involvement in future clinical research. Colorectal Cancer Clinical Research Forum (CCCRF), Kobe, 2014.11.28
- Kazuko Nobori: Activities of certified pharmacists for HIV infection and pharmacotherapy. 2014 Hyogo Prefecture Hospital Pharmacist Workshop, Kobe, 2014.11.29
- Megumi Aburaya: Efficacy and Safety Evaluation of Cancer Chemotherapy in Diabetic Patients -Coordination between Basic and Clinical Studies-. 4th University-Medical Cooperation Lecture, Kobe, 2014.12.01
- Miho Nagai: Forward and backward coordination of pharmacotherapy. Taiho Pharmaceutical Co., Ltd. 3rd Port Island Medical and Nursing Collaboration Meeting, Kobe, 2014.12.03
- Naoki Shibatani, Shiho Sato, Shiori Yumiki, Ryosuke Suzuki, Shuichi Kishimoto, Noriaki Kitada, Kazuko Nishioka, Takuya Aoki, Shinya Yoshioka, Nobuo Inotume, Toru Hashida, Shoji Fukushima: Effects of β2-adrenaline on ritodrine hydrochloride in patients with threatened preterm labor Effect of receptor gene polymorphism. The 35th Annual Meeting of the Japanese Society of Clinical Pharmacology, Matsuyama, 2014.12.04
- Sadatomo Oku: Lecture at the 70th training session of the Hyogo Prefecture Diabetes Association Nutrition Committee. Hyogo Prefecture Diabetes Association Nutrition Committee Workshop, Kobe, 2014.12.06
- Toru Hashida: Preventing Human Errors in High-Risk Drugs -Cases of Anticancer Drugs-. Drug Safety Management Workshop, Tokyo, 2014.12.6
- Mieko Ooto: Lecture on medical safety training, ``Ingenuity to prevent incidents due to delirium''. 2014 Kobe Chuo Branch Public Interest Incorporated Association Hyogo Prefecture Nursing Association, Kobe, 2014.12.13
- Masaki Hirabatake: New development of pharmacist work in cancer chemotherapy. The 7th Pharmacist Seminar, Hyogo Prefecture Cancer Cooperation Council, Kobe, 2015.01.17
- Chihiro Noma, Sadatomo Oku, Mai Ikemura, Misao Sakuma, Shigefumi Morimoto, Noriaki Kitada, Kenji Uriuhara, Toru Hashida: Early intervention by pharmacists in drug therapy during the perioperative period and its evaluation - Medication management at pre-hospital examination centers - The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.24
- Sadatomo Oku: Seamless drug treatment from pre-hospitalization to post-discharge. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.24
- Inazumi T: Use of acetaminophen injections in our hospital. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.24
- Yuki Kasai, Masaki Hirabatake, Nanako Kawaguchi, Toru Hashida: Changes in serum calcium levels according to renal function and administration of calcium and vitamin D in patients treated with denosumab. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.25
- Hidetoshi Fujiwara: Ward pharmacy work required by regional medical cooperation. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.25
- Masaki Hirabatake, Shigefumi Morimoto, Haruna Yamamoto, Noriaki Kitada, Toru Hashida: Guidance and management of cancer patients based on pharmacist outpatient services. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.25
- Masaki Hirabatake, Hiroki Ito, Yuko Yagi, Hiromichi Nomura, Shinya Nakanishi, Akiko Matsushita, Toru Hashida: Measures against hepatitis B caused by immunosuppression and chemotherapy. Kinki Block Cancer Pharmacist Forum, Osaka, 2015.02.07
- Tomomi Tatsumi, Mai Ikemura, Toru Hashida: Examination of bleeding frequency and background factors associated with alteplase administration. 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
- Tadashi Kazama, Motozumi Ando, Shigefumi Morimoto, Toru Hashida: A study on sex differences in hematotoxicity in R-B therapy for malignant lymphoma. 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
- Megumi Aburaya, Mai Ikemura, Toru Hashida: Fact-finding survey on the implementation of cancer chemotherapy in diabetic patients - Aiming to establish an effective and safe cancer chemotherapy -. 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
- Yuki Kasai, Masaki Hirabatake, Nanako Kawaguchi, Toru Hashida: Changes in serum calcium levels according to renal function and administration of calcium and vitamin D in patients treated with denosumab. 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
- Chihiro Noma, Sadatomo Oku, Mai Ikemura, Motozumi Ando, Misao Sakuma, Shigefumi Morimoto, Noriaki Kitada, Kenji Uryuhara, Toru Hashida: Early intervention by pharmacists in drug therapy during the perioperative period and its evaluation - pre-hospital examination center medication management in 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
- Kazumi Fujita, Mai Ikemura, Toru Hashida: Evaluation of liver deviating enzymes at the onset of phenytoin-induced liver injury. 4th Floor Japanese Pharmacist Resident Forum, Tokyo, 2015.02.07
- Shigefumi Morimoto: My thoughts on the functions of pharmacists in medical care. Kansai POS drug study group, Osaka, 2015.02.07
- Masaki Hirahata: Involvement of pharmacists in oral anticancer drugs. The 16th Nishi Municipal Hospital Drug-Drug Collaboration Open Conference, Kobe, 2015.02.10
- Yuriko Sugiyama: Efforts of pharmacists before hospitalization - Aiming for seamless hospitalization -. The 15th Kobe Diabetes Team Medical Study Group, Kobe, 2015.02.13
- Chihiro Sugihara, Sachiko Muranaka, Yuji Agawa, Eriko Kobiki, Mariko Takenaka, Naoki Higashibeppu, Hiroaki Nishioka: Report on ward NST activities at a stroke center. The 30th Annual Meeting of the Japanese Society for Parenteral and Enteral Nutrition, Kobe, 2015.02.13
- Hashida, Toru: Creating a Safe and Rewarding Workplace - Strategy for Zero Exposure to Anticancer Drugs and Career Considerations -. Osaka City University Cancer Professional Training Plan Lecture, Osaka, 2015.2.13
- Toru Hashida: On the seamless implementation of collaboration between diagnosis and medicine, which is now required of pharmacists. Osaka Pharmaceutical University 7th Cancer Pro Symposium, Takatsuki, 2015.2.15
- Shinji Nakayasu: Pharmacokinetics of drugs, interactions, blood concentration measurement of drugs. Japanese Nursing Association 2014 Infection Control Certified Nurse Training Program, Kobe, 2015.02.19
- Shigefumi Morimoto: Further Enhancement of Efforts toward Personalization of Cancer Drug Therapy -Looking to the Future-. National Hospital Organization 2014 training for promotion of team medical care 2 (cancer chemotherapy), Osaka, 2015.2.19
- Toru Hashida: Expanding and deepening needs for pharmacists - good luck for the ocean of medical care -. 2014 Aichi Kouseiren Pharmacist Association General Assembly, Nagoya, 2015.2.21
- Toru Hashida: Prescription Proposals and Outcomes Based on Agreement Between doctor and Pharmacists, 2014 Health Labor and Welfare Scientific Research Grants. Investigation and outcome evaluation symposium on team medical care and community medical care by pharmacists, Tokyo, 2015.2.22
- Shinji Nakayoku: Management of bring-your-own-medicine based on drug-drug cooperation -considering the current situation and prospects-. Hyogo Prefecture Hospital Pharmacists Association 2014 2nd Small and Medium-sized Hospital Diagnosis Department Workshop, Kobe, 2015.03.05
- Shigefumi Morimoto: How do pharmacists respond to “individualization” in cancer care? “Individualized” response to gastrointestinal cancer. Japanese Society of Clinical Oncology Annual Meeting 2015 Symposium 5, Kyoto, 2015.03.15
- Nomura H, Hirabatake M, Nakanishi S, Yagi Y, Tsuji A, Hashida T: Safety of high-dose cisplatin administration using short hydration. Japanese Society of Clinical Oncology Annual Meeting, Kyoto, 2015.03.15
- Toru Hashida: Considering Safe Handling of Pharmaceuticals. The 9th Hyogo Branch Academic Conference of the Japanese Society of Health Management, Ono, 2015.03.15
- Sadatomo Oku: ``Responsibility and trust required of pharmacists'' - For seamless drug treatment -. Web Symposium for Pharmacists, Tokyo, 2015.03.16
- Eriko Obiki, Naoki Shibatani, Sadachi Oku, Shigefumi Morimoto, Toru Hashida: Practical training program for training pharmacists with practical abilities. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.26
- Motozumi Ando, Eriko Kobiki, Shinji Nakayoku, Yuko Kashiwagi, Noriaki Kitada, Shigefumi Morimoto, Hiroki Kamei, Satomi Sono, Hiroaki Nishioka, Takeshi Fukuda, Toru Hashida: Safety evaluation and pharmacokinetic effects of the anti-MRSA drug daptomycin Factor analysis. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.26
- Masaki Hirahata: Prevention of exposure to anticancer agents and countermeasures against side effects. Osaka Rosai Hospital Open Conference, Osaka, 2015.03.26
- Toru Hashida: Safety management of cancer chemotherapy by pharmacists - Controlling occupational exposure to anticancer drugs and adverse reactions -. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.26
- Toru Hashida: Establishment of pharmacist outpatient clinic and community medicine. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.28
- Toru Hashida: The role of pharmacists required for telemedicine in the near future. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.28
2013 Magazine announcement
book
- Hashida Toru, Kitada Noriaki, Harada Naoko, Nagano Toru (partial author). 11 Skin diseases, 77 Herpes zoster. Pharmacy March 2014 special issue, Drugs and tests 2014 Drug treatment and medication guidance practical guide. Nanzando, Tokyo, Japan. 990-1003, 2014
paper
- Noriaki Kitada, Kengo Kanamori, Ayako Konishi, Shoji Tanaka, Yoshiki Suginoshita, Tetsuro Inokuma, Toru Hashida: Elucidation of the factors affecting the treatment period for liver cancer using sorafenib. Cancer and Chemotherapy 40 : 479-82, 2013
- Mayumi Omichi, Noriaki Kitada, Kazuko Tobiko, Shoji Tanaka, Yoshinori Taji, Akihiro Yoshimoto, Takao Suzuki, Shoji Fukushima, Toru Hashida: Analysis of Correlation Between Mean Weekly Darbepoetin Alfa Dose and Hemoglobin Level in Peritoneal Dialysis Patients .Japanese The Japanese Society for Dialysis Therapy 46: 419-26, 2013
- Shinji Nakayoku, Noriaki Kitada, Kenji Yamamoto, Koichi Ariyoshi, Toru Hashida: Medical support for large-scale disaster-stricken areas -Trends in prescriptions at first-aid stations and logistical support using group pages-. 16: 589-94, 2013
Review, etc.
- Kitada, Noriaki, Hashida, Toru: Hospital ward pharmacy work to start from now on-obtaining hints from precedent cases-how to manage brought-in medicines. 953-7, 2013
- Noriaki Kitada: I understand the symptoms and how to deal with them! 9th - Side effects and management of anticancer drugs. Breast cancer. weekly PTX monotherapy. Monthly Pharmaceutical Affairs 55: 1330-6, 2013
2013 academic conference presentations and lectures
- Eriko Obiki, Motozumi Ando, Noriaki Kitada, Shinji Nakayu, Yuko Kashiwagi, Kenji Yamamoto, Hiroaki Nishioka, Toru Hashida: Monitoring of blood concentration of daptomycin and study on its safety. The 30th Annual Meeting of the Japan Society of TDM, Kumamoto, May 26, 2013
- Makiko Dohi, Mai Ikemura, Shinji Nakayado, Noriaki Kitada, Toru Hashida: Actual use of acid secretion inhibitors in patients with Clostridium difficile infection in the severe department. Medical Pharmacy Forum 2013/The 21st Clinical Pharmacy Symposium, Kanazawa, July 18, 2013
- Naoki Shibatani, Naoko Harada, Miho Nagai, Noriaki Kitada, Toru Hashida: Hospital ward pharmacy work support and its evaluation from the drug information room using a tablet terminal. The 16th Annual Meeting of the Japan Society for Drug Information, Nagoya, August 10, 2013
- Haruna Yamamoto, Noriaki Kitada, Naoki Shibatani, Masaki Hirabatake, Toru Hashida: How to provide information for minimizing risks when introducing new drugs - denosumab as an example -. The 16th Annual Meeting of the Japan Society for Drug Information, Nagoya, August 11, 2013
- Nomura H, Hirabatake M, Nakanishi S, Kitada N, Tsuji A, Hashida T: Factor analysis of renal injury due to high-dose cisplatin. The 11th Annual Meeting of the Japanese Society of Medical Oncology, Sendai, August 31, 2013
- Hitomi Mizutani, Shigeru Tsuruya, Kazuko Nishioka, Noriaki Kitada, Masaru Yamakawa, Toru Hashida: Characteristics and preparation of high-calorie transfusion in low birth weight infants. The 16th Annual Meeting of the Japanese Society for Injectable Drug Clinical Information, Nishinomiya, August 31, 2013
- Toshihiko Inazumi, Keisuke Kongo, Yukari Satsuma, Mieko Ooto, Noriaki Kitada, Setsuko Umeda, Mio Lee, Toru Hashida: Intervention and evaluation by pharmacists in palliative care outpatient clinics. The 7th Annual Meeting of the Japanese Society of Palliative Medicine, Chiba, September 15, 2013
- Tadashi Kazama, Noriaki Kitada, Yutaka Hasegawa, Toru Hashida, Tsuneo Hamaguchi: Effect of sex difference on hematotoxicity in R-CHOP therapy for non-Hodgkin's lymphoma. The 23rd Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Sendai, September 21, 2013
- Kanako Okusada, Chiyo Yamamoto, Kazuko Nobori, Noriaki Kitada, Takayuki Ishikawa, Toru Hashida: Necessity of pharmacist outpatient services for patients taking Bcr-Abl tyrosine kinase inhibitors. The 23rd Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Sendai, September 21, 2013
- Nakanishi, M., Hirabatake, M., Nomura, H., Kitada, N., Hamada, M., Sato, K., Satake, Y., Kotake, T., Tsuji, A., Hashida, T.: Fact-finding survey of injection site injury caused by fosaprepitant and warm compress method for vascular pain. effect. The 51st Annual Meeting of the Japan Society of Clinical Oncology Clinical Oncology, Kyoto, October 25, 2013
- Mika Kumagai, Mai Ikemura, Shinji Nakayado, Yuko Kashiwagi, Noriaki Kitada, Toru Hashida: Effects of vancomycin powder on renal function in patients with severe infections. The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
- Nami Kinjo, Satoshi Oku, Mai Ikemura, Noriaki Kitada, Kenji Uriuhara, Toru Hashida: Clarification and evaluation of pharmacist intervention criteria for drug therapy in the perioperative period-Management of antithrombotic drugs at the pre-hospital examination center- . The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
- Takeshi Yonezawa, Satoshi Okusada, Nami Kinjo, Naoki Shibatani, Noriaki Kitada, Kenji Uryuhara, Toru Hashida: Observance of antithrombotic drug discontinuation instructions at the pre-hospital examination center. The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
- Nanako Kawaguchi, Naoko Harada, Naoki Shibatani, Noriaki Kitada, Tetsuro Inokuma, Toru Hashida: Occurrence of renal dysfunction and anemia in triple therapy with chronic hepatitis C. The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
- Ayano Hashiguchi, Hirohito Hama, Hiromi Higuchi, Noriaki Kitada, Hidehisa Masai, Toru Hashida: Construction of an electronic medical record allergy history information extraction system and its application to ward pharmacy work. The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
- Shinji Nakayoku, Motozumi Ando, Takuro Hayashi, Akira Inoue, Koichi Ariyoshi, Noriaki Kitada, Toru Hashida: A case of bradycardia due to elevated blood levels of atenolol in an elderly patient undergoing maintenance hemodialysis. The 34th Annual Meeting of the Japanese Society for Clinical Toxicology, Western Japan, Hirakata, February 22, 2014
- Chiyo Yamamoto, Kanako Okusada, Kazuko Nobori, Noriaki Kitada, Kei Irie, Yutaka Okada, Nobuhiro Hiramoto, Naoko Hashimoto, Takayuki Ishikawa, Toru Hashida: Immunization of neurokinin 1 receptor antagonist administration in pretreatment for allogeneic hematopoietic stem cell transplantation Effect of inhibitors on blood concentration. The 36th Annual Meeting of the Japanese Society for Hematopoietic Cell Transplantation, Okinawa, March 8, 2014
- Shibatani Naoki, Nakasone Aki, Sato Shiho, Kishimoto Shuichi, Kitada Noriaki, Nishioka Kazuko, Aoki Takuya, Kita Masato, Inotsume Nobuo, Hashida Toru, Fukushima Shoji: Effects of genetic polymorphisms on systemic clearance of ritodrine in patients with threatened premature birth. The 134th Annual Meeting of the Pharmaceutical Society of Japan, Kumamoto, March 30, 2014
- Noriaki Kitada: Administration management of anticancer drugs. Kobe City Medical Center General Hospital Cancer Clinic Open Seminar, Kobe, September 12, 2013
- Ayano Hashiguchi, Hirohito Hama, Hiromi Higuchi, Noriaki Kitada, Hidehisa Masai, Toru Hashida: Construction of an electronic medical record allergy history information extraction system and application to ward pharmacy work. 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
- Nanako Kawaguchi, Eriko Kobiki, Naoko Harada, Naoki Shibatani, Noriaki Kitada, Toru Hashida: Occurrence of anemia and acute renal failure in chronic hepatitis C triple therapy. 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
- Mika Kumagai, Mai Ikemura, Haruna Yamamoto, Shinji Nakayasu, Yuko Kashiwagi, Noriaki Kitada, Toru Hashida: Effect of oral vancomycin powder administration on renal function in patients with severe infections. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
- Risa Shimizu, Chiyo Yamamoto, Kanako Okusada, Noriaki Kitada, Toru Hashida: After completion of pharmacist residency training program at Kobe City Medical Center General Hospital. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
- Yuki Kasai, Mai Sakai, Mai Ikemura, Masaki Hirabatake, Noriaki Kitada, Toru Hashida: The development of peripheral neuropathy due to subcutaneous administration of bortezomib and problems seen from the viewpoint of pharmacists. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
- Tatsuya Hirano, Yuki Takase, Hidetoshi Fujiwara, Noriaki Kitada, Toru Hashida: Investigation of blood concentration measurement and renal damage of Neoral® in interstitial pneumonia 2 hours after administration. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
- Arisa Takahashi, Miho Nagai, Masaki Hirabatake, Noriaki Kitada, Toru Hashida: Current status of measures against hepatitis B caused by chemotherapy in oral chronic myelogenous leukemia drugs. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
- Nami Kinjo, Takeshi Yonezawa, Satoshi Oku, Mai Ikemura, Noriaki Kitada, Toru Hashida: Introduction and evaluation of pharmacist intervention criteria for patients taking antithrombotic drugs at prehospital examination centers. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
- Noriaki Kitada: Practical and Case Summary of Pharmaceutical Intervention -Gastrointestinal Cancer-. The 1st Japanese Society of Pharmaceutical Health Care and Sciences 1st lecture on how to write case summaries for cancer pharmacist certification application, Tokyo, May 19, 2013
- Toru Hashida: Building an organization for new development of ward pharmacy and training pharmacists, Pharmaceutical Management Meeting 2013, Tokyo, May 25, 2013
- Toru Hashida: Hospital duties carried out by new-generation Pharmacy, The 36th Tokushima University Postgraduate Education Public Lecture, Tokushima, June 1, 2013
- Toru Hashida: New business development and career paths for hospital pharmacists, Yamaguchi Prefectural Hospital Pharmacists Association Pharmaceutical Research Group, Yamaguchi, June 2, 2013.
- Shinji Nakayu: "Trial of blood concentration monitoring in patients receiving daptomycin", Seminar on MRSA infections, Kobe, July 10, 2013
- Noriaki Kitada: Team medical care in outpatient clinics - management of administration of oral anticancer drugs. The 6th Awaji Island cancer treatment collaboration promotion seminar, Sumoto, July 25, 2013
- Toru Hashida: Total Management of Anticancer Drugs, Kinki Block Cancer Chemotherapy Certified Pharmacist Seminar, Osaka, August 24, 2013
- Toru Hashida: A pharmacist of the new age who promotes team medical care, 1st post-graduate training course, Faculty of Pharmacy, Iwate Medical University, Morioka, August 25, 2013
- Toru Hashida: Team-based cancer care and the role of pharmacists—oncology pharmacists, 3rd Cancer Professional Symposium, Osaka University of Pharmaceutical Sciences, Takatsuki, August 26, 2013
- Toru Hashida: Total management of injectable anticancer drugs, The 16th Annual Meeting of the Japanese Society for Injectable Drug Clinical Information, Nishinomiya, August 31, 2013
- Noriaki Kitada: Administration management of oral anticancer drugs using drug-drug collaboration. The 1st Port Island Pharmaceutical Collaboration Meeting, Kobe, September 11, 2013
- Shinji Nakayaku: "Infection control system from pharmacist's point of view" 2013 Fall Lecture, Kansai Branch of Japan Society for Medical Informatics, 47th Regular Meeting of Kansai Medical Information Processing Conference, Osaka, September 14, 2013
- Toru Hashida: Building an organization for new development of ward pharmacy work and training pharmacists, Nara Hospital Pharmacists Association 93rd Academic Lecture, Nara, September 26, 2013
- Toru Hashida: Pharmacy Business Management and Human Resource Development -From the Perspective of Hospital Management-, Kanshin District National Hospital Pharmacists Association, 5th Pharmacy Department Managers Workshop, Tokyo, October 5, 2013
- Sadatomo Oku: "About pharmacotherapy for diabetes," Diabetes Education Seminar 2013 hosted by the Hyogo Prefecture Federation of Diabetes Educators, Kobe, October 14, 2013.
- Noriaki Kitada: Pharmaceutical management for perioperative risk avoidance. 19th Bayer Medical Pharmacy Seminar Kobe, Kobe, October 16, 2013
- Toru Hashida: Aiming for seamless drug treatment between hospitals and communities, Special Symposium of the Pharmaceutical Subcommittee, The 52nd National Association of Municipal Hospitals in Kyoto, October 18, 2013.
- Noriaki Kitada: Total management of cancer drug therapy. The 36th Okayama Prefectural Hospital Pharmacists Association Cancer Drug Therapy Study Group, Okayama, October 19, 2013
- Toru Hashida: New development of hospital pharmacy business - Expanding needs and human resource development -, The 38th Japanese Red Cross Clinical Pharmacy Workshop, Nagoya, November 3, 2013
- Toru Hashida: Total management of anticancer drugs, Hiroshima Prefectural Hospital Pharmacist Association Academic Lecture, Hiroshima, November 15, 2013
- Masaki Hirabatake: "Proposal for Optimal Regimen", Meet The Specialist (Eli Lilly Japan/ Hyogo Prefecture Hospital Pharmacist Association) Kobe, November 27, 2013
- Toru Hashida: Building an organization for new development of ward pharmacy work and training pharmacists, Saiseikai 2013 pharmacy Director workshop, Tokyo, December 13, 2013.
- Toshihiko Inazumi: Seamless Support for Cancer Patients -What is Required of Pharmacists- "Pain Management for Cancer Patients", 4th Hyogo Prefecture Pharmacist Association Training Department Lecture, Kobe, December 15, 2013.
- Shinji Nakayu, Eriko Kobiki: "Selection of Anti-MRSA Drugs and TDM," Nishi-Kobe Medical Center Clinical Laboratory Open Conference, Kobe, March 5, 2014
- Noriaki Kitada: Total management of cancer drug therapy. The 3rd Shiga cancer drug therapy conference, Moriyama, March 5, 2014
"Pharmacist Resident Manual 3rd Edition" Igaku Shoin, Tokyo, 2021, Toru Hashida, Hiroaki Nishioka (Editors).
For pharmacists in their first or second year after graduation, we have compiled information that is useful in the field in a crisp, pocket-sized format. General topics include dispensing, injection, DI, examination, and physical assessment. The specifics explain 52 major diseases such as cardiovascular disease, gastrointestinal disease, cancer, etc., in the order of "understanding the patient's condition → treatment (standard prescription example) → pharmacist's pharmaceutical care → points for prescription proposal". The pharmacy department and general medicine department of our hospital put all their efforts into writing this article.
"The iron rule of a pharmacist resident" Toru Hashida, Hiroaki Nishioka (Editors). Igaku Shoin, Tokyo, 2016
This is a book for pharmacists in their first and second years after graduation to develop their "practical skills" when solving clinical pharmaceutical problems. Based on educational cases and situations selected by senior pharmacists, we introduce guidelines and papers that support a deeper understanding of drug treatment. Tips for practicing evidence-based drug therapy and Pitfalls & Tips for new pharmacists are summarized as "iron rules" in an easy-to-understand manner.
Recruitment information
Business content
Fundamental to our role is the correct and safe provision of drug therapy for the benefit of our patients. We are actively promoting the digitalization of pharmacy operations, such as operating a robot dispensing room, and are working to enhance and expand ward and outpatient pharmacist operations to ensure the safety of drug therapy and improve adherence. In addition, pharmacists at the pre-hospitalization preparation center, internal medicine confirmation outpatient clinic, and community medicine promotion center support both before and after inpatient care, and provide drug therapy in consideration of the patient's lifestyle in order to connect drug therapy from the hospital to the community. , is also involved in self-reliance support. We are looking for a partner who can demonstrate creativity and put it into action. Let's work hard together.
education system
Utilizing the pharmacist resident system and training programs for new staff, we are training pharmacists with a clinical mindset by enhancing their study mindset. The guidance system is also substantial, and senior pharmacists have adopted a mentor-mentee system ("roof tile education" system) where senior pharmacists serve as consultation desks for work and academic activities. We have built a continuous educational system from practical training to post-graduation education for residents and new employees, and training for specialist pharmacists, and we value an environment where all staff can learn and grow together.
Working environment
We value an environment where our energetic staff can work together to maximize their potential.
・Each department, such as the central department and the ward department, has developed it so that it can be practiced voluntarily and cross-departmentally.
・We are using robots and IoT technology to improve the efficiency of our operations.
・We hold regular pharmacy department executive meetings, all-hands meetings, and education team meetings to share information and exchange opinions, thereby verifying pharmacist work and education effects and leading to further improvements.
・Each department, such as the central department and the ward department, has developed it so that it can be practiced voluntarily and cross-departmentally.
・We are using robots and IoT technology to improve the efficiency of our operations.
・We hold regular pharmacy department executive meetings, all-hands meetings, and education team meetings to share information and exchange opinions, thereby verifying pharmacist work and education effects and leading to further improvements.
message from senior
We not only provide central services such as dispensing, injections, and co-injection of anticancer drugs, but also ensure that outpatients and hospitalized patients can continue optimal drug treatment safely and securely, both before and after hospitalization. provides pharmaceutical care to The pharmacy department has many young staff members and is extremely lively, creating an environment in which it is easy to convey various opinions and ideas with the aim of improving operations. By linking questions discovered through daily work to clinical research and turning previously unknowns into known, there are chances to contribute to safer and more appropriate drug treatment. Would you like to practice drug treatment with us on the front line in collaboration with multi-professionals?
